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Phenotypic screens, which focus on measuring and quantifying discrete cellular changes rather 
than measuring affinity for individual recombinant proteins, have recently attracted renewed 
interest as an efficient strategy for drug discovery. In this paper, we describe the discovery of a 
new chemical probe, bisamide (CCT251236), identified using an unbiased phenotypic screen to 
detect inhibitors of the HSF1 stress pathway. The chemical probe is orally bioavailable and 
displays efficacy in a human ovarian carcinoma xenograft model. By developing cell-based SAR 
and using chemical proteomics, we identified pirin as a high affinity molecular target, which was 
confirmed by SPR and crystallography. 
INTRODUCTION 
Despite the recent extraordinary progress seen in cancer therapy using molecularly-targeted 
drugs, the disease commonly remains stubbornly resistant to effective long term treatment. Even 
when excellent responses to drugs are initially observed, resistance is almost inevitable and 
patients are then left with few treatment options1 as the discovery of targeted therapies in 
oncology has focused on relatively few protein families.2 To break this cycle and expand the 
treatment options for cancer patients, new approaches are needed to discover novel druggable 
protein targets.3 
In phenotypic screens, small molecules undergo high-throughput screening against intact cells, 
rather than recombinant proteins, and discrete phenotypic changes in the cell are measured and 
quantified.4 Interest in phenotypic screens has increased significantly in recent years, due to their 
potential to effectively discover new drugs.5 Phenotypic screens have several advantages over 
screens using recombinant proteins. Hits from a phenotypic screen will, by definition, be cell 
permeable and have cellular activity, potentially reducing optimization cycles and timelines. 
Also, because the screening approach is unbiased, established knowledge of the biology of 
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molecular targets is not required. Finally, polypharmacology is often observed with small 
molecules and structurally related protein families; this can be crucial for efficacy and is 
perfectly compatible with a phenotypic screening approach.6 
In contrast, progressing hits from a phenotypic screen can generate a number of unique 
challenges. Discovering pharmacodynamic (PD) biomarkers in vivo for use in animals can be 
difficult when developing hits from phenotypic screens, as the pathways commonly need to be 
activated with an external stimulus.7 Cell-based screens are typically more expensive and time-
consuming, so may require a greater commitment prior to the screening campaign.8 Furthermore, 
molecular target identification, deconvolution and validation are crucial steps if new chemical 
probes9 and drugs are to be discovered. These are often a bottle-neck in phenotypic screening.10 
Even with successful target deconvolution, the target discovered may not be of interest; for 
example, the target may already be drugged or be a known anti-target. Finally, 
polypharmacology may be a serious impediment to compound progression, because the 
interaction with multiple structurally related protein targets may prove impossible to 
deconvolute.11 These challenges alter the balance between prioritizing druglike properties of 
compounds and an efficient target identification strategy.12 
To execute a successful phenotypic screening campaign, it is critical to select an appropriate 
phenotype for small molecule intervention. Heat-shock factor protein 1 (HSF1) is a transcription 
factor and the master regulator of the ancient, canonical heat-shock response.13 A large body of 
work has verified the importance of HSF1 to tumorigenesis and cancer progression.14 HSF1 has 
been proposed to be activated by various elements of the cancer state, potentially reprogramming 
the transcriptome in a way that is overlapping with, but distinct from, the heat-shock response.15 
Also, a strong correlation has been reported between the expression of activated HSF1 in tumors 
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and adverse clinical outcomes.16 This evidence indicates that the inhibition of HSF1-mediated 
transcription could be a viable strategy in cancer treatment.17 Moreover, inhibiting the HSF1 
stress pathway would represent an attempt at targeting non-oncogene addiction and proteotoxic 
stress, which has been proposed to be advantageous.18 However, HSF1 is a ligandless 
transcription factor so is unlikely to be amenable to standard drug discovery strategies and direct 
inhibition with small molecules. Therefore, we proposed that an inhibitor of HSF1-mediated 
transcription, which antagonized the HSF1 pathway but without necessarily binding directly to 
HSF1, could be discovered and developed via a cell-based phenotypic screen. 
RESULTS 
HSF1 Phenotypic Assay. To observe HSF1-mediated transcription in an in vitro setting, the 
HSF1 pathway is activated by a validated heat-shock protein 90 (HSP90) inhibitor,19 or another 
form of external stress,20 which initiates the heat-shock response. Commonly, the output of the 
heat-shock response is quantified by measuring the induction of heat-shock 70 KDa protein 1 
(HSP72) expression, the stress-inducible HSP70 isoform.19 HSF1 pathway inhibitors are then 
defined by their ability to block the induction of HSP72. Several HSF1-mediated HSP72 
induction inhibitors have been discovered via this method with different proposed molecular 
mechanisms of action (Figure 1).21,28 
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Figure 1. Inhibitors of HSF1-mediated HSP72 induction 
With the aim of discovering novel hit-matter that inhibits HSF1-mediated transcription, we 
previously carried out a cell-based high-throughput phenotypic screen in U2OS human 
osteosarcoma cells of ~200,000 compounds, including ~35,000 compounds from a kinase-
focused library.22 The screen quantified the inhibition of HSP72 induction using the Arrayscan 
assay28 following treatment with the HSP90 inhibitor tanespimycin (17-AAG).23 
The Bisamide Series. Using this screen, we identified a potent hit from the kinase-focused 
deck, bisamide 1 (CCT245232) (Figure 2).24 Following re-synthesis, the screening hit was 
confirmed and displayed a pIC50=8.55±0.09 (IC50=2.8 nM, n=49)25 in our HSP72 cell-based 
enzyme-linked immunosorbent assay (ELISA) in U2OS cells. The HSP72 cell-based ELISA 
assay is an alternative assay format to the Arrayscan assay for quantifying the induced 
expression of HSP72 and was used as our primary phenotypic pathway assay throughout the 
study.26 The IC50 was defined as the concentration that inhibited the signal to 50% of the 17-
AAG (250 nM) induced HSP72 expression, relative to the control 17-AAG alone (see supporting 
information for details). The clear structural feature defining this chemotype was the N,N’-4-
methyl-1,3-phenylenediamide core (Figure 2). 
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Figure 2. HSF1 pathway inhibitor, bisamide 1 
We had previously demonstrated that pan cyclin-dependent kinase (CDK) inhibitors, and 
potent CDK9 inhibitors in particular which act as transcription antagonists27, can inhibit HSF1-
mediated HSP72 induction phenotype; therefore, we initially suspected a similar mechanism for 
this chemotype.28 However, upon biochemical screening of bisamide 1 against CDK2 and CDK9, 
no inhibition was observed (<10 % inhibition at 1 µM, see supporting information). Therefore, 
we hypothesized that bisamide 1 was acting through a different mechanism of action and 
consequently was submitted for further characterization. 
Hit Characterization – Kinase Activity. HSF1 is regulated by multiple post-translational 
phosphorylations,29 so we hypothesized that kinase inhibition other than CDK2 and CDK9 was 
causing the observed HSF1-mediated HSP72 induction inhibition. Therefore, bisamide 1 was 
screened against a broad kinase set using the KINOMEscan biochemical screening platform, a 
binding assay which gave single-point percentage inhibition values at 1 µM (DiscoverX, 
http://www.discoverx.com).30 Analysis of this data set for 442 kinases revealed that bisamide 1 
inhibited only 9 kinases >50% and 4 kinases >90% (see supporting information for details). To 
validate the kinase hits, orthogonal functional assays were carried out on the 4 kinases that 
displayed >90% inhibition. Of these, KIT, PDGFRA and PDGFRB failed to confirm in their 
respective functional assays, all returning pIC50<5 (IC50>10000 nM). Bisamide 1 did display 
modest activity against BRAF, returning a pIC50=6.38 (IC50=420 nM, n=1).31 Although it seemed 
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unlikely that the modest biochemical BRAF activity would translate into cellular activity, seven 
commercially available32 potent BRAF inhibitors of differing chemotypes were tested in our 
cellular HSF1-mediated HSP72 induction inhibition assay for comparison and none displayed 
pIC50>5 (IC50<10000 nM).33 This indicated that BRAF inhibition was not an important 
contributor to the observed HSF1 transcription inhibition phenotype (see supporting 
information). 
Hit Characterization – Cellular. To establish whether bisamide 1 displays cellular activity 
without activation of the heat-shock response using the HSP90 inhibitor 17-AAG, the growth 
inhibitory effects were assayed in the U2OS cell line using the CellTiter-Blue (CTB) assay 
(Promega). Following four days of treatment, bisamide 1 displayed a highly potent 
pGI50=7.74±0.08 (GI50=18 nM, n=13), when compared to vehicle. To assess the broader single 
agent cellular activity of 1, the compound was assayed for growth inhibition against a large, 
genetically-diverse panel of human cancer cell lines (Genomics of Drug Sensitivity in Cancer, 
www.cancerrxgene.org).34 Of the 635 cell lines assayed, 628 (99%) displayed a pGI50>6 
(GI50<1000 nM), 455 (72%) a pGI50>7 (GI50<100 nM) and 18 (2.8%) a pGI50>8 (GI50<10 nM), 
with no clear selectivity against any specific tissue type (see supporting information for details). 
These results suggested that bisamide 1 had wide-ranging anti-cancer activity and that activation 
of the HSF1 pathway with an HSP90 inhibitor was not required for 1 to inhibit cancer cell 
growth. 
Cell-Based SAR. Given the complexity of factors underlying cell-based structure activity 
relationships (SAR), we focused on matched pair changes to establish which features were 
crucial for the cellular activity of the bisamide chemotype. There were two primary aims to our 
medicinal chemistry strategy. Firstly, because our biochemical kinase screening had failed to 
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reveal any potential kinase targets, a broader target identification strategy would need to be 
developed. Secondly, although bisamide 1 had excellent cellular potency, the compound had 
poor aqueous solubility (kinetic solubility <2 µM), which would need to be addressed to validate 
HSF1 pathway inhibition as an anti-cancer strategy in an in vivo human tumor xenograft model. 
Both goals required us to improve our understanding of the cellular SAR, particularly to identify 
a vector-to-solvent through which either a chemical probe linker or a solubilizing group could be 
attached, without disrupting the ability of the compound to bind to the primary pharmacological 
target or targets. 
To develop the cell-based SAR, we switched to the human ovarian carcinoma cell line SK-
OV-3, which was relatively sensitive to growth inhibition and is commonly used in translational 
drug discovery both in vitro35 and in vivo.36 When the activity of bisamide 1 in the SK-OV-3 cell 
line was assayed, it gave a pIC50=7.17±0.07 (IC50=68 nM, n=4) using the HSP72 cell-based 
ELISA assay induced with 250 nM 17-AAG. Bisamide 1 also inhibited the proliferation of SK-
OV-3 cells in the CTB assay with a pGI50=8.08±0.12 (GI50=8.4 nM, n=12).  
Scheme 1. Synthesis of the benzodioxane bisamide replacements 
 
Reagents and conditions: (i) Oxalyl chloride, DMF, DCM; then, pyridine, DCM. (ii) Fe, NH4Cl, 
EtOH/H2O. (iii) RPhCO2H, HATU, DIPEA, DMF. 
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We first focused the exploration on the benzodioxane motif (Scheme 1). The left-hand ring 
system analogues (Table 1, Entries 1-6) were synthesized via a three-step procedure from the 
commercially available 2-methyl-5-nitroaniline 2. Following amide bond formation, through the 
reaction of 2-methyl-5-nitroaniline 2 with 2-methylquinoline-6-carboxylic acid 3, and 
subsequent reduction of the nitro-group using iron, the second amide bond was generated using 
the corresponding carboxylic acid in a HATU-mediated coupling to afford the various 
benzodioxane analogues in good to moderate yields. 
Table 1. Bisamide analogues 
Entry Compd Structures 
SK-OV-3 
pIC50±SEM 
(IC50, n)
a,b 
SK-OV-3 
pGI50±SEM 
(GI50, n)
a,c 
Pirin SPR 
pKD±SEM  
(KD, n)
a,d 
1 1 
 
 
7.17±0.07 
(68 nM, n=4) 
8.08±0.12  
(8.3 nM, n=12) 
7.42±0.03  
(38 nM, n=3) 
2 6 
 
<5.00  
(>10000 nM, n=2) 
<6.00  
(>1000 nM, n=2) 
ND 
3 7 
 
<5.00  
(>10000 nM, n=2) 
<6.00  
(>1000 nM, n=2) 
<6.00  
(>1000 nM, n=3) 
4 8 
 
6.35±0.07  
(450 nM, n=3) 
7.26±0.09  
(55 nM, n=3) 
7.57±0.01  
(27 nM, n=3) 
5 9 
 
5.59±0.09  
(2600 nM, n=4) 
6.37±0.12  
(430 nM, n=5) 
7.74±0.03  
(18 nM, n=3) 
6 10 
 
<5.00  
(>10000 nM, n=2) 
<6.00  
(>1000 nM, n=2) 
7.57±0.03  
(27 nM, n=3) 
7 11 
 
 
 
<5.00  
(>10000 nM, n=2) 
<6.00  
(>1000 nM, n=2) 
ND 
8 12 
 
<5.00  
(>10000 nM, n=2) 
<6.00  
(>1000 nM, n=2) 
ND 
9 13 
 
<5.00  
(>10000 nM, n=2) 
<6.00  
(>1000 nM, n=2) 
<6.00  
(>1000 nM, n=3) 
10 14 
 
<5.00  
(>10000 nM, n=2) 
<6.00  
(>1000 nM, n=2) 
ND 
11 15 
 
 
7.92±0.25  
(12 nM, n=5) 
8.60±0.11  
(8.6 nM, n=4) 
ND 
12 16 
 
7.29±0.23  
(51 nM, n=6) 
8.29±0.05  
(5.1 nM, n=3) 
ND 
13 17 
 
6.65±0.09  
(220 nM, n=6) 
8.05±0.08  
(8.9 nM, n=7) 
7.42±0.00  
(38 nM, n=3) 
 
 
 
 
 
 
 
 
 
 
 
 
N NH
O
O
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a
All results are quoted as the geometric mean±SEM. pIC50/pGI50/pKD=-log IC50/GI50/KD (M). 
The number of repeats, n, are described in parentheses. ND=Not determined. 
b
Cell-based ELISA 
assay for inhibition of HSP72 induction; SK-OV-3 cells were pretreated with compound at the 
relevant concentration for 1 hour before the addition of 250 nM 17-AAG. HSP72 levels were 
then quantified after 18 hours. 
c
Growth inhibition was measured after 96 hours of treatment and 
compared to vehicle control. 
d
pKD values were measured through analysis of the sensorgram at 
equilibrium where possible. Values were then fitted to a one-site specific binding model using 
Graphpad Prism Version 6. 
Changing the 5-substituted dioxane isomer 1 (Table 1, entry 1) to the 6-substituted dioxane 
isomer 6 (Table 1, entry 2) resulted in a complete loss of cellular activity (pIC50<5), indicating 
that the isomer of the benzodioxane was crucial. The acyclic dimethoxy analogue 7 (Table 1, 
entry 3) also displayed a complete loss of cellular activity. Next, we investigated the role of the 
two oxygen atoms of the dioxane ring. Removing the para-oxygen of the dioxane to give the 
meta-chroman 8 (Table 1, entry 4) resulted in a modest 5-fold decrease in cellular HSF1-
mediated HSP72 induction inhibition and a 7-fold decrease in growth inhibition compared to 1; 
while the para-chroman isomer 9 (Table 1, entry 5) displayed a further 6-fold decrease in HSF1-
mediated HSP72 induction inhibition and an 8-fold decrease in growth inhibition compared to 8, 
which represents a 37- and 51-fold decrease in cellular activity respectively compared to the 
original hit, bisamide 1. Surprisingly, isochroman 10 (Table 1, entry 6) displayed no measurable 
cellular activity. From these results, it was clear that the benzodioxane moiety was crucial for the 
cellular activity of the bisamide series. Because the SAR surrounding the benzodioxane was 
steep and complex, we decided that this region was unlikely to be solvent exposed, so would be 
incompatible with linker and solubilizing group attachment. 
Secondly, we investigated the role of the central ring and amide moieties in the cellular activity 
of the bisamide chemotype. We hypothesized that the amide groups could play an important role 
in hydrogen bonding with a potential target and in controlling the overall shape of the ligand, 
while substitution at the central ring could lead to the discovery solvent-exposed vectors. The 
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synthesis of these analogues (Table 1, Entries 7-10) was similar to that described in Scheme 1. 
Substitution at both the 6-position (Table 1, entry 7) and the 4-position (Table 1, entry 8) of the 
central benzene ring resulted in a complete loss of cellular activity, suggesting that neither of 
these vectors represented a viable route to solvent. Owing to the potential for the toluene methyl 
group to affect the conformation of the right-hand amide, we decided to leave this group 
unchanged. N-Methyl substitution of the left-hand amide (Table 1, entry 9) and an attempted 
sulfonamide bioisosteric replacement (Table 1, entry 10) also resulted in a complete loss of 
cellular activity. Again, owing to the steep SAR in this region of the chemotype, it was clearly 
incompatible with linker and solubilizing group attachment. 
Finally, we examined the role of the 2-methylquinoline ring in the cellular activity of the 
bisamide series. All analogues (Table 1, Entries 11-13) were synthesized via a method similar to 
that described in Scheme 1. Firstly, we removed the 2-methyl group, which is both lipophilic and 
has the potential to be a weak hydrogen bond donor, to give quinoline 15 (Table 1, entry 11). 
Removal of this group resulted in no significant change in the cellular activity when compared to 
1 (Table 1, entry 1). Next we moved the quinoline nitrogen from the 1- to the 3-position, to give 
isoquinoline 16 (Table 1, entry 12). Again, no significant change in cellular activity was 
observed when compared to bisamide 1. Finally, we partially reduced the quinoline ring to give 
tetrahydroquinoline 17 (Table 1, entry 13). By changing to tetrahydroquinoline 17, the nitrogen 
atom now acts as a hydrogen bond donor rather than an acceptor. Despite this reversal in 
anticipated binding properties, only a 3.5-fold decrease in HSF1-mediated HSP72 induction 
inhibition and no significant change in antiproliferative activity was observed when compared to 
bisamide 1. The broad SAR of the quinoline region of the molecule suggested that this moiety is 
solvent exposed, so could therefore be exploited for solubilizing group and linker attachment. 
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Exploiting Vectors-to-Solvent – Solubilizing Group Optimization. Owing to the 
complexities of the cellular SAR, attaching a solubilizing group to the solvent-exposed region of 
the ligand was considered a more expeditious strategy to generate an in vivo chemical probe 
suitable for use in animal models, rather than attempting to optimize the intrinsic solubility of the 
bisamide series without insight from structural information. To address this objective, we 
adopted an iterative strategy to exploit the rapid synthesis of analogues that would exhibit 
improved physicochemical properties and demonstrate the appropriate mouse pharmacokinetic 
(PK) parameters for in vivo study (Scheme 2). 
Scheme 2. Synthesis of solubilizing group analogues 
 
Reagents and conditions: (i) Oxalyl chloride, DMF, 1,4-benzodioxane-6-carboxylic acid DCM; 
then, 4-methyl-3-nitroaniline, pyridine, DCM, RT; then Pd/C (10%), H2 (1 atm), EtOH. (ii) NaH, 
RCH2OH, THF, 0 
o
C to reflux. (iii) n-BuLi, CO2(s), THF, -78 
o
C. (iv) HATU, DIPEA, DMF, RT. 
The optimal route to the synthesis of these analogues would be to introduce the solubilizing 
group via nucleophilic aromatic substitution on the quinoline as the final step; however, this 
failed due to consistently low yields. Therefore, the solubilizing group was introduced at the start 
of the synthesis. Formation of the precursor carboxylic acid 19 was achieved via lithium halogen 
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exchange of the corresponding arylbromide 20. The resulting bisamides were then assayed for 
cellular activity and in vitro PK parameters (Table 2). 
Table 2. Optimization of the bisamide solubilizing group 
 
Entry Compd Sol. Group 
SK-OV-3 
pGI50±SEM 
(GI50, n)
a 
MLM Clint 
(µL/min/mg)b 
KS 
(µM)c 
LogD7.4
d 
Calculated 
pKa (MoKa)
e 
1 1  
8.08±0.12 
(8.3 nM, n=12) 
35 1 2.6 NA 
2 21 
 
8.37±0.06  
(4.3 nM, n=3) 
92 5 3.3 NA 
3 22 
 
8.94±0.10  
(1.1 nM, n=4) 
170 90 2.0 9.5 
4 23 
 
8.13±0.18  
(7.4 nM, n=4) 
76 7 2.9 7.7 
5 24 
 
8.87±0.09  
(1.3 nM, n=8) 
24 40 2.4 9.7 
6 25 
 
8.97±0.03  
(1.1 nM, n=6) 
57 30 2.5 8.8 
7 26 
 
8.65±0.10  
(2.2 nM n=25) 
23 70 2.1 8.9 
a
pGI50=-log GI50 (M); geometric mean±SEM, n=number of biological repeats in parentheses. 
For the corresponding SK-OV-3 HSP72 cell-based ELISA data see the supporting information. 
b
Mouse liver microsome (MLM) assay was carried out at Cyprotex, arithmetic mean of n=2. In 
vitro Clint is calculated from the half-life using standard procedures. Assumes the fraction 
unbound in the assay is 1.37 
c
Kinetic Solubility (KS) measured via an in-house HPLC method 
from phosphate buffer at pH 7.4, all values quoted to 1 SF, the dynamic range of the assay is 1-
100 µM, arithmetic mean of n=2. dMeasured via an in-house HPLC method, arithmetic mean of 
n=2, all values quoted to 2 SF.38 
d
MoKa version 2.5.2, all values quoted to 2 SF. See supporting 
information for details. 
We first attached the oxygen-linked ether chain to give glycol 21 (Table 2, entry 2). No 
significant decrease in either HSF1-mediated HSP72 induction inhibition (see supporting 
information) or the antiproliferative activity was observed when compared to lead bisamide 1 
(Table 2, entry 1). This suggested firstly, the oxygen linker had no detrimental effect on activity 
and secondly, that this region of the molecule was indeed solvent exposed. To carryout multi-
 
 
 
 
 
 
O N
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parameter optimization of the solubilizing group, we used four in vitro properties to assess each 
compound's potential for in vivo mouse PK: microsomal stability, kinetic solubility at pH 7.4, 
lipophilicity as measured by LogD7.4 and the predicted basicity of the solubilizing group. The 
glycol 21 displayed an increase in lipophilicity compared to lead bisamide 1; this increase was 
reflected in the 2.4-fold decrease in microsomal stability with a modest increase in kinetic 
solubility. However, glycol 21 remained a low solubility compound, which is inconsistent with 
good oral bioavailability. From these data, we concluded that the compound would need to be 
charged to deliver the correct balance of properties. To introduce a charged moiety, we first 
focused on the dimethylamine group with a 3-carbon linker. Dimethylamine 22 (Table 2, entry 3) 
displayed no significant change in cellular activity, despite this analogue now being 
predominately charged at physiological pH, according to the calculated pKa. Consistent with its 
cationic character, dimethylamine 22 displayed a 1.4 log unit decrease in lipophilicity when 
compared to 21, which was accompanied by an 18-fold improvement in kinetic solubility. 
Unfortunately, the decrease in lipophilicity was not reflected in an improvement in microsomal 
stability. We hypothesized that this was due to oxidation of the N-methyl groups, so we moved to 
cyclic amines to reduce the CYP450 mediated degradation. Morpholine 23 (Table 2, entry 4) 
showed little improvement in microsomal stability or kinetic solubility when compared to 21. 
Analysis of the LogD7.4 and calculated pKa for morpholine 23 suggested that the solubilizing 
group was not sufficiently basic to balance the physicochemical properties of the compound. 
Moving to piperidine 24 (Table 2, entry 5), we observed a better balance in physicochemical 
properties, with the reduction in lipophilicity reflected in improvements in both microsomal 
stability and kinetic solubility. However, piperidine 24 was predicted to be highly basic and we 
were concerned that this would have a detrimental effect on permeability, and therefore on oral 
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bioavailability. To reduce the basicity of the solubilizing group without increasing lipophilicity, 
we reduced the linker length to give 25 (Table 2, entry 6), thereby exploiting the inductive effect 
of the oxygen. Despite the 0.9 log unit decrease in predicted basicity, the kinetic solubility and 
lipophilicity were unchanged. Unfortunately, 25 displayed a decrease in microsomal stability, so 
we reduced the ring size to give pyrrolidine 26 (CCT251236, Table 2, entry 7),24 which displayed 
the desired balance of in vitro properties, while maintaining excellent cellular activity with a 
pIC50=7.73±0.07 (IC50=19 nM, n=15, see Table S3 in the supporting information for details) for 
inhibition of HSF1-mediated HSP72 induction. The free GI50 in SK-OV-3 cells was then 
calculated from the free fraction in the cell assay, which gave a free GI50=1.1 nM.39 Western 
blotting confirmed that pyrrolidine 26 blocked the HSF1-mediated induction of both HSP72 and 
HSP27 as representative heat shock proteins, following treatment with the HSP90 inhibitor 17-
AAG. Also, qPCR analysis demonstrated that 26 inhibited the induction of HSP72 at the mRNA 
level, clearly blocking the induction of HSPA1A gene expression with a pIC50=7.40 (IC50=40 
nM, n=1, see supporting information). Taking these results together, pyrrolidine 26 was selected 
for in vivo study. 
Mouse Pharmacokinetics (PK). To assess the potential of bisamide 26 as an in vivo chemical 
tool to study HSF1-mediated transcriptional activity inhibition, the compound was dosed in 
BALB/c mice at 5 mg/Kg as an oral solution and iv bolus. Blood concentrations were then 
measured over a 24 hour period (Table 3). 
Table 3. Mouse blood PK parameters for bisamide 26 
Mouse 
Dose 
po/iv 
(mg/Kg) 

	
  
(h*nM)a 
Blood Cl 
(mL/min/Kg)
a 
Vss 
(L/Kg)a 
Half-
life (h) 
%F fub
b 
,
	

(h*nM)c 
Clu 
(mL/min/Kg)d 
Vdu 
(L/Kg)e 
BALB/c 5/5 
5800 
(8100-4200) 
9.2  
(12-7.3) 
4.2 
(6.3-2.8) 
5.3 39 0.0083c 48 1100 510 
Athymic 20/0 
1900  
(2800-1400) 
NA NA NA NA 0.015d 29 NA NA 
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All values are quoted to 2 SF. The 90% confidence intervals (CI) are in parentheses. NA=not 
applicable. 
a
The geometric mean of n=3 individual mice. 
b
fub=fup/B:P, 
c
fup=0.010 (0.011-
0.0097), B:P@1 µM=1.2:1 (1.4-1.0). dfup=0.025 (0.030-0.020), B:P@1 µM=1.7:1 (1.7-1.7). 
c
AUCu=AUC*fub. 
d
Clu=Cl/fub. 
e
Vdu=Vss/fub. 
Analysis of the mouse PK data revealed that bisamide 26 possessed low total blood clearance 
(10% hepatic blood flow)40 and moderate oral bioavailability, with a half-life sufficient to allow 
once-a-day dosing. In vitro assessment of the plasma protein binding and the blood to plasma 
ratio revealed that 26 was highly bound to plasma proteins (~99%); therefore, the unbound 
clearance was high, with a low free exposure from the 5 mg/Kg oral dose, equivalent to free Cav
0-
24h=2.0 nM.41,42 The high unbound volume of distribution indicates that 26 readily binds to 
tissues, consistent with the basicity of the compound.43 
Bisamide 26 Displays Efficacy in a Human Ovarian Carcinoma Xenograft Model. Despite 
the high unbound clearance of bisamide 26 in mouse, the good oral bioavailability, half-life and 
excellent in vitro cellular activity (free GI50=1.1 nM) encouraged us to test the potential efficacy 
of 26 in an in vivo human tumor xenograft model. Based on the free Cav
0-24h=2.0 nM observed in 
non-tumor bearing immunocompetent BALB/c mice following the 5 mg/kg po qd dose, a 20 
mg/kg po qd dose in immunodeprived athymic mice was selected to cover ~10-times the in vitro 
free GI50 in SK-OV-3 cells.44 To our surprise, following this 20 mg/kg po dose, the free exposure 
was actually a disappointing AUCu
0-24h=29 h*nM, equivalent to free Cav
0-24h=1.2 nM (Table 3, 
see supporting information for details). Despite the lower than expected free exposure of 
bisamide 26, this dose still represented coverage of the in vitro free GI50 in SK-OV-3 cells and 
was well tolerated in a mouse multi-dose tolerability study;45 therefore, the 20 mg/kg po qd dose 
was selected for further investigation.46 
SK-OV-3 cells were injected subcutaneously into athymic mice for tumor formation. Once 
tumors were established, the mice were randomized into treatment and control groups and were 
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dosed orally once-a-day with either vehicle or 20 mg/kg of bisamide 26. Tumor volumes and 
mouse body weights were measured throughout and tumor weights were measured at the end of 
the study, while total tumor concentrations were measured 2 and 6 hours post final dose. (Figure 
3 and supporting information). 
 
Figure 3. Efficacy of bisamide 26 against SK-OV-3 human ovarian carcinoma xenograft model 
Blue: vehicle control n=8, Red: 26 20 mg/kg po qd n=8, (Vehicle=10% DMSO, 90% of a 25% 
(2-hydroxypropyl)-β-cyclodextrin in 50 mM citrate buffer pH 5). Error bars: arithmetic 
mean±SEM. Dosing breaks were carried out on days 5-12, 14, 16, 18, 20, 22, 24, 26, 29, 31 
The mice were dosed intermittently throughout the study with 26 to maintain their condition, 
as assessed through monitoring body weights (see supporting information). Clear therapeutic 
efficacy was observed with bisamide 26, with a Tumor Growth Inhibition (%TGI)47 of 70% 
based on final tumor volumes. The study was terminated after 33 days and comparison of the 
control and treated arms indicated a 64 % reduction in mean tumor weights (p=0.015)48 with total 
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tumor concentrations of 26 as high as 940 nM, consistent with the compound’s basicity and high 
volume of distribution (see supporting information). 
Target Identification. Following the successful efficacy study, the potential for bisamide 26 
as a chemical probe to study the effects of HSF1 transcription inhibition, both in vitro and in 
vivo, were clear. However, the variety of HSF1 transcription inhibitors in the literature49 suggests 
there are multiple mechanisms through which this phenotype may be observed, each with 
differing potential for drug discovery. 
To decipher the molecular mechanism of the bisamide series, we needed to discover their 
protein targets. The potency of the bisamide 26 in cell-based assays suggests that only high 
affinity efficacy and epistatic targets would be of interest.11 Our biochemical kinase screening 
had indicated that there were no high affinity kinase targets. We therefore expanded our 
biochemical screening to include other protein families. Bisamide 26 was submitted to the Cerep 
Diversity Screen (Cerep, http://www.cerep.fr) comprising 98 molecular targets, including 
receptors and enzymes, measured at 10 µM.50 Analysis of these screening data revealed that 
bisamide 26 displays a good selectivity profile. Only six targets (the receptors: adenosine A2A 
and A3, histamine H2 and H3, muscarinic and the enzyme acetylcholine esterase) displayed >80 
% inhibition and these generally represented the highly promiscuous receptor protein targets (see 
supporting information for details). No hits displayed sufficient activity to clearly relate the 
molecular target to the efficacious free concentrations achieved in vitro or in vivo. 
Because no clear protein families had been revealed from our biochemical screening, a 
different approach was necessary. We decided to exploit a chemical proteomics strategy and 
using our knowledge of the cellular SAR, we designed a protein pull-down chemical probe to 
identify high affinity molecular targets from a human cancer cell lysate (Figure 4). 
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Figure 4. Tool compounds for target identification. All quoted cellular activities are in the SK-
OV-3 cell line, the numbers of repeats are in parentheses 
To carry out the chemical proteomics pull-down strategy, the bisamide warhead would need to 
be attached via a linker to a solid-phase bead, without disrupting binding to the molecular target 
or targets. The solubilizing group vector was the obvious choice for the linker attachment, but to 
test whether cellular activity was maintained, amide 27 was designed as a cell-permeable mimic 
of the solid-phase probe. Pleasingly, amide 27 maintained excellent cellular potency (SK-OV-3 
pGI50=8.04±0.06, GI50=9.1 nM, n=4), so amine 29 was used for attachment to the bead via amide 
bond formation. In addition to bisamide 26, tetrahydroquinoline 17 was selected as a second 
positive control due to its distinct structural difference. These two compounds would be used to 
displace specific molecular targets from the solid-phase probe. Also, to help distinguish false 
positives from the pull-down experiment, a physicochemically-matched negative control was 
designed. The dioxane isomer 6 (Table 1, entry 2) had previously been shown to lose all cellular 
activity. To physicochemically match the dioxane isomer 6 to bisamide 26, the same ethoxy 
pyrrolidine solubilizing group was attached to give isomer 28, which, as expected, displayed no 
measurable cellular activity. 
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With all four probe molecules in hand, the compounds were submitted to the stable isotope 
labeling by amino acids in cell culture (SILAC) mass-spectrometry based pull-down assay 
(Evotec, https:www.evotec.com) to identify and quantify molecular targets of the bisamide series 
from the lysate of SK-OV-3 cells. Every protein captured by the bead, whether specific or non-
specific, is analyzed in this methodology by quantitative mass spectrometry. By using SILAC to 
quantify the relative amounts of protein captured from the lysate, this approach can, in principle, 
determine the apparent affinity of every stable protein in the lysate for the surface-bound 
bisamide probe, although particularly low abundance proteins may not be discovered via this 
method and proteins that are unstable to the lysis conditions would not be detected. 
Displacement of the captured proteins with the free active bisamides 26 and 17, then allows for 
estimation of their apparent affinities for specific protein targets. Proteins that are apparently 
displaced from the bead-bound probe by the inactive isomer 28 are considered non-specific or 
irrelevant for the cellular activity and discarded. The putative protein targets can then be ranked 
based on their affinity for further investigation (Table 4, see supporting information for details).51 
Table 4. Molecular targets from the pull-down assay using the bisamide probes in SK-OV-3 cell 
lysate 
 
Protein 
Protein EC50 
(µM)a 
26 AC50 
(µM)b 
26 Ki
app 
(µM)c 
17 AC50 
(µM)b 
17 Ki
app 
(µM)c 
28 AC50 
(µM)b 
GSK3β 1.3 1.2 NA 10 NAd NAa 
Pirin 1.3 1.5 0.028 10 0.19 NAa 
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A: SK-OV-3 cell lysate protein binding curves for immobilized 29. B: protein displacement 
curves for pyrrolidine 26. Curves are an average of two different mixing conditions. EC50 and 
AC50 are determined from analysis of the curves without limits. 
a
EC50 is the apparent 
immobilized bisamide probe concentration at which 50% of the available protein is bound. The 
probe bisamide is assumed to be >10-fold molar excess over proteins in the lysate. 
b
AC50 is the 
apparent free bisamide concentration at which 50% of the protein is displaced from the 
immobilized bisamide probe. At least 2-fold enrichment of bound proteins when compared to the 
matrix.
 c
Ki
app
 values are estimated using the Cheng-Prusoff equation, apparent [29-
immobilized]=67 µM,52 assuming no mass transport limitation, interactions are purely 
competitive and all interactions are direct. dNot Applicable (NA) – Ki
app
 cannot be calculated if 
the interaction with the probe is indirect. 
Analysis of these data from the quantified chemical proteomics pull-down experiment revealed 
very few molecular targets of the bisamides, consistent with the selectivity observed with our 
biochemical screening. After excluding highly promiscuous proteins commonly observed in pull-
down experiments,53 three putative targets were identified. PDE6D displayed only weak apparent 
affinity for the bead-bound probe and little selectivity between active (26 and 17) and inactive 
(28) probes, so was not considered further. GSK3β displayed apparent high affinity for both 
active analogues, with no apparent affinity for the inactive analogue. However, GSK3β had 
previously been assayed in our biochemical kinase screening and both binding and functional 
assays (see supporting information) had demonstrated that the bisamide series have no 
measurable affinity for this kinase; we therefore concluded that GSK3β was potentially an 
indirect target of the bisamide series. The final putative protein target was pirin. The binding 
curve for pirin to the bead-bound bisamide probe was quite shallow; however, the displacement 
curves for pirin, which were very similar to the displacement curves for GSK3β with both cell 
active probe ligands, gave robust data with an apparent Ki=28 nM for 26 and no affinity was 
observed with the inactive control. Using this method on a SK-OV-3 cell lysate, pirin emerged as 
the only remaining putative target of the bisamide series.54 
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Pirin Validation. Very little is known about pirin and few papers have been published 
discussing its possible function. Pirin was first identified in 1997 by Wendler et al. from a yeast 
two-hybrid screen to discover interactors of the transcription factor NFI/CTF1. Pirin was 
described as an iron-binding, metal-dependent protein, predominately localized within the 
nucleus, highly conserved across species and ubiquitously expressed across all tissue types.55 
Following this initial discovery, Scheidereit et al. reported that human pirin interacts with the 
proto-oncoprotein, BCL3, linking pirin with the NFκB pathway.56 The role of pirin in the NFκB 
pathway was further demonstrated by Lui et al.; using SPR, they revealed the metal-dependent 
formation of a pirin/p65/DNA complex and hypothesized the role of human pirin to be a redox-
sensing transcription factor regulator.57 The redox activity of pirin has previously been discussed, 
as the expression level of pirin is proposed to be under the control of the transcription factor 
NRF2 through changes in cellular oxidative stress.58 Wang et al. previously reported that human 
pirin interacts with the tumor suppressor protein EAF2/U19 and that exogenous overexpression 
of pirin increased colony formation in LNCaP human prostate cancer cells.59 In the human 
melanoma cell line WM266.4, Alcalay et al. demonstrated that shRNA knockdown of pirin could 
induce a senescence phenotype and suppress colony formation.60 Also in the WM266.4 cell-line, 
Osada et al. demonstrated that siRNA knockdown of pirin could suppress cell migration.61,62 
These results are consistent with the observation by Simizu et al. that siRNA knockdown of pirin 
suppressed migration of human adenocarcinoma HeLa cells and that pirin was important for 
epithelial-mesenchymal transition (EMT).63 However, little evidence has emerged of an 
antiproliferative phenotype from genetic inhibition of pirin expression and our in-house data 
using siRNA in SK-OV-3 cells was consistent with this finding.64 Nonetheless, because our 
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original screening paradigm was designed to discover inhibitors of transcription, the proposed 
role of pirin as a redox-sensitive transcription factor regulator was certainly intriguing.  
To confirm pirin as a high affinity molecular target of the bisamide series, we needed to assess 
the affinity of the compounds and establish SAR in an orthogonal assay format. Pirin has no 
known catalytic function and no known endogenous ligand in mammalian cells, consequently we 
decided to focus on surface plasmon resonance (SPR) to measure the affinity of the bisamide 
series for pirin. Purified recombinant human pirin was attached to the SPR chip through a 
standard amide coupling. The affinity of the bisamide ligand was assessed by equilibrium 
analysis of the resulting sensorgram (Figure 5). 
 
Figure 5. Representative SPR sensorgram and binding isotherm of bisamide 26 bound to 
recombinant pirin. The dotted-line represents the time-point the equilibrium response was 
measured. The binding isotherm was fitted to a one-site specific binding model using Graphpad 
Prism 6 
The known pirin ligand TPh A61 was used as a positive control and to protect the binding site 
during amine coupling to the SPR chip, but displayed only modest affinity in our hands 
(pKD=5.77±0.04, KD=1700 nM, n=4).65 The SPR sensorgram showed that bisamide 26 is indeed a 
tight-binding ligand of pirin. Equilibrium analysis revealed that bisamide 26 had a 
pKD=7.36±0.01 (KD=44 nM, n=3). However, the ratio of theoretical Rmax to measured Rmax from 
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the binding isotherm was 0.40, indicating apparent substoichiometric binding. This could be due 
to the coupling of pirin to the SPR chip impairing protein folding or because pirin is a metal-
dependent protein and the metal was leaching out into the running buffer; both effects could 
negatively impact the apparent binding affinity and stoichiometry. 
To establish the SAR surrounding pirin binding, several bisamide analogues were selected for 
further study. We first focused on the two other analogues used in target identification. The cell 
active analogue tetrahydroquinoline 17 (Table 1, entry 13) was also found to display tight-
binding affinity for pirin; in contrast, the negative control dioxane isomer 28 (pIC50<5.00, 
IC50>10000 nM, n=2) displayed no measurable affinity. These data suggested that pirin SAR and 
the cellular SAR were linked. Increasing the steric bulk of the solubilizing group, as exemplified 
by piperidine 24 (Table 2, entry 4) again returned a high affinity pirin ligand (pKD=7.52±0.02, 
KD=30 nM, n=3), consistent with the potent cellular activity. However, structural changes to the 
benzodioxane amide motif proved more complex. The original hit, bisamide 1 (Table 1, entry 1), 
was a tight-binding pirin ligand; whereas the cell inactive analogues, methylated amide 13 (Table 
1, entry 9) and dimethoxy 7 (Table 1, entry 3), displayed no affinity for pirin. However, the two 
chroman isomers 8 and 9 (Table 1, Entries 4 and 5) were tight-binding ligands for pirin but their 
target affinity did not reflect their decrease in cellular activity when compared to bisamide 1. 
Finally, the isochroman analogue 10 (Table 1, entry 6) was still a high affinity ligand for pirin, 
despite displaying no cellular activity (see Table S11 supporting information for details). 
Pirin is a member of the cupin super family of proteins which are so called because they all 
possess a conserved β-barrel.66 However, due to minimal sequence homology between members 
of the cupin family, crystallography is often needed to identify them. The cupins display a huge 
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array of functionality, including oxidases and isomerases.67 To better understand pirin SAR, we 
determined the crystal structure of efficacious bisamide 26 bound to pirin (Figure 6). 
 
Figure 6. X-ray crystal structure of bisamide 26. PDB 5JCT, Pymol image of pirin (light blue 
cartoon representation) in complex with bisamide 26 (cyan stick representation), 2 Fo-Fc map 
contoured at 1.0 σ (blue mesh) and Pymol image of pirin (magenta, blue stick representation) in 
complex with bisamide 26 (cyan stick representation), distances shown are in Ångstroms, 2 Fo-
Fc map contoured at 1.0 σ (blue mesh). Crystals belonged to the space group P212121 and 
diffracted to resolution of 1.73 Å 
Pirin is a metal-binding bicupin characterized by the two β-barrels that are clearly visible in 
the crystal structure.68 Pirin binds a single metal-ion in one of the β-barrels, which is where a 
deep, small molecule binding pocket is located. The metal-ion is clearly visible in the electron 
density, although it is unclear which metal-ion is actually bound. The metal-ion binding site is 
formed of three histidine residues (His56, His58 and His101), a glutamic acid (Glu103) and two 
water molecules, showing the metal-ion possesses octahedral coordination. Bisamide 26 forms 
no direct interactions with the metal-ion, instead a water-mediated interaction is created by the 
two amide functional groups, which form a hydrogen bonding pincer around this metal-
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coordinated water molecule, revealing why the two amides are crucial for binding. The methyl-
distal amide also acts as a hydrogen-bond donor with an aspartic acid (Asp43) at the base of the 
binding site, explaining why methylation of that group is not tolerated. The methylpyridine ring 
of the quinoline substituent is clearly solvent exposed and the solubilizing group cannot be 
resolved due to flexibility, consistent with the broad SAR at this position and the eventual 
success of the pull-down probe. The SAR around the benzodioxane ring is less clear. From the 
cellular SAR, the oxygen atoms of the dioxane are crucial for activity. The narrow binding site is 
consistent with the cellularly-inactive dioxane isomer 28 and the cellularly-inactive dimethoxy 
analogue 7 having low affinity for pirin (Table 1 and Table S11), as both these groups would 
cause a steric clash. However, there are no clear interactions between the protein and the dioxane 
ring oxygens, so it is unsurprising that changing the positions of the oxygen atoms has little 
effect on pirin affinity, such that chromans 8, 9 and isochroman 10 (Table 1, Entries 4-6) still 
display high affinity for pirin, in contrast to their complex cellular SAR. 
The apparent disconnect between the pirin affinity SAR and the antiproliferative cellular SAR, 
led us to hypothesize that either simply binding to pirin was not enough to recapitulate the 
cellular phenotype or that binding to a second molecular target was also crucial. For example, in 
the study by Lui et al.57 the formation of protein-protein interactions with pirin was under the 
allosteric control of the redox-state of the iron bound in the protein. Ligands bound in the metal-
binding site are therefore likely to act in an allosteric manner to regulate the function of pirin. It 
is commonly known that allosteric modulators display complex SAR, where small structural 
changes can have little effect on protein affinity but can drastically alter the observed phenotype, 
switching ligands between positive, negative and neutral allosteric modulation.69,70 The 
alternative hypothesis consistent with the observed complex cellular SAR was that a second high 
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affinity protein target was required to explain the antiproliferative activity of the bisamide 26 and 
was not detected in our target-ID campaign due to either low abundance or poor stability in the 
lysate. The dual targeting of proteins is often observed; for example, CDK4 and CDK6, where 
simultaneous inhibition of both kinases is necessary to observe an antiproliferative phenotype,71 
owing to the similarity of their respective binding sites, small-molecule inhibitors inevitably 
inhibit both proteins.72 RNAi knockdown of pirin by several groups has demonstrated very 
limited effects on cell proliferation and as pirin has no known enzymatic function, discovering 
and validating a cellular biomarker to investigate its role in the antiproliferative phenotype and in 
vivo efficacy is an ongoing challenge. 
One phenotype that has previously been associated with a small-molecule binding to pirin is 
cancer cell migration.61 Miyazaki et al. demonstrated that their pirin ligand, TPh A, inhibited the 
migration of the melanoma cell line, WM266.4.61 To investigate whether our tool compound, 
bisamide 26, phenocopied this distinct pirin-ligand chemotype, we decided to investigate its anti-
migratory activity using a scratch-wound assay. The scratch-wound assay is commonly used to 
assess the effects of small-molecules on cell migration.73 Bisamide 26 demonstrated excellent 
antiproliferative activity against the WM266.4 cell line (pGI50=7.92±0.10, GI50=12 nM, n=11). 
To exclude the effect of inhibiting proliferation on migration in the scratch-wound assay, the 
cells were plated at high confluency and the time-frame of the assay was reduced to 30 h. The 
relative wound-density was then measured at various concentrations and time-points. The 
negative control isomer 28 displayed no measurable anti-migratory activity in stark contrast to 
the potent pirin ligand bisamide 26, which was able to strongly inhibit the migration of 
WM266.4 cells at 100 nM (Figure 7). 
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Figure 7. The anti-migratory activity of chemical probe bisamide 26. A: wound healing images 
of WM266.4 cells, after 30 h the wound has almost completely healed in the control in contrast 
to 100 nM 26. B: quantification of the relative wound density reveals the maximum anti-
migratory activity is achieved at 100 nM 26. 
DISCUSSION 
Bisamide 26 displays excellent and wide-ranging in vitro cellular potency, inhibiting both 
HSF1-mediated transcriptional activity (defined by the inhibition of the induced expression of 
the heat-shock proteins HSP72 and HSP27 and HSPA1A mRNA) and cancer cell proliferation. 
Also, 26 has good mouse PK, and demonstrated its anticancer effects in vivo at low free 
exposures with clear tumor growth inhibition at tolerable doses. Kinase screening and broader 
proteome screening, in addition to the chemical proteomics using SILAC quantified pull-down 
with rigorous controls and follow-up testing, indicate that pirin was the sole specific protein 
target that could be identified to date. SPR analysis of the binding of the bisamide series to pirin 
confirms that these compounds are high affinity ligands, with most aspects of the pirin SAR 
being consistent with the cellular SAR. However, there was an apparent disconnect surrounding 
the dioxane group of the chemotype. This requires further investigation to determine whether 
pirin is crucial for the in vitro antiproliferative activity and in vivo efficacy via an allosteric 
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modulation mechanism or whether binding to a second high affinity protein target is needed to 
fully account for the observed phenotype. Because the SILAC quantified pulldown assay can 
only identify protein targets that are stable to cell lysis, additional in-cell target-ID methods are 
currently under investigation to probe for a potential second target. Nevertheless, the tool 
compound, bisamide 26, demonstrated the previously proposed anticancer phenotype of pirin 
ligands, by inhibiting the migration of WM266.4 melanoma cells in vitro. The role of pirin in the 
bisamide phenotype and the cellular effects of modulating the HSF1 pathway with bisamide 26 
are currently also under investigation and will be reported subsequently. 
CONCLUSIONS 
Using a high-throughput screen to identify inhibitors of the HSF1-mediated stress pathway, we 
have discovered an extremely potent inhibitor of human cancer cell proliferation in vitro from 
the bisamide chemotype. By exploring the SAR from the cellular assays, we designed a chemical 
probe, bisamide 26, which is highly potent and displays an appropriate mouse pharmacokinetic 
profile to significantly inhibit growth in a human ovarian carcinoma xenograft model. The 
chemical probe 26 was also used to design a chemical proteomic pull-down experiment, which 
identified the putative transcription factor regulator, pirin as a protein target. The high affinity of 
chemical probe 26 for pirin was confirmed by SPR. Comparison of the biophysical with the 
cellular data indicated that active molecules bind pirin, but that the cellular SAR is more 
complex, although 26 did display a potent inhibitory effect on the migration of human melanoma 
cells, consistent with the putative pirin cancer phenotype. Despite this, we propose that bisamide 
26, combination with the physicochemically matched negative control dioxane isomer 28, are 
promising chemical probes to investigate the role of HSF1 pathway inhibition and pirin binding 
in vitro and in vivo. 
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EXPERIMENTAL SECTION 
Experimental Procedures (Chemistry) 
All final compounds were screened through our in-house computational PAINS filter and gave 
no structural alerts as potential assay interference compounds.74 Unless otherwise stated, 
reactions were conducted in oven dried glassware under an atmosphere of nitrogen or argon 
using anhydrous solvents. All commercially obtained reagents and solvents were used as 
received. Thin layer chromatography (TLC) was performed on pre-coated aluminum sheets of 
silica (60 F254 nm, Merck) and visualized using short-wave UV light. Flash column 
chromatography was carried out on Merck silica gel 60 (partial size 40-65 µm). Column 
chromatography was also performed on a Biotage SP1 purification system using Biotage Flash 
silica cartridges (SNAP KP-Sil). Ion exchange chromatography was performed using acidic 
Isolute Flash SCX-II columns. Semi-preparative HPLC was performed on an Agilent 6120 
system, flow 20 mL/min, eluents 0.1 % acetic acid in water and 0.1 % acetic acid in methanol, 
gradient of 10 % to 100 % organic phase. 1H-NMR spectra were recorded on Bruker AMX500 
(500 MHz) spectrometers using an internal deuterium lock. Chemical shifts are quoted in parts 
per million (ppm) using the following internal references: CDCl3 (δH 7.26), MeOD (δH 3.31) 
and DMSO-d6 (δH 2.50). Signal multiplicities are recorded as singlet (s), doublet (d), triplet (t), 
quartet (q) and multiplet (m), doublet of doublets (dd), doublet of doublet of doublets (ddd), 
broad (br) or obscured (obs). Coupling constants, J, are measured to the nearest 0.1 Hz. 13C-
NMR spectra were recorded on Bruker AMX500 spectrometers at 126 MHz using an internal 
deuterium lock. Chemical shifts are quoted to 0.01 ppm, unless greater accuracy was required, 
using the following internal references: CDCl3 (δC 77.0), MeOD (δC 49.0) and DMSO-d6 (δC 
39.5). High resolution mass spectra were recorded on an Agilent 1200 series HPLC and diode 
array detector coupled to a 6210 time of flight mass spectrometer with dual multimode APCI/ESI 
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source or on a Waters Acquity UPLC and diode array detector coupled to a Waters G2 QToF 
mass spectrometer fitted with a multimode ESI/APCI source. Analytical separation was carried 
out according to the methods listed below. The mobile phase was a mixture of methanol (solvent 
A) and water (solvent B), both containing formic acid at 0.1 %, UV detection was at 254 nm. 
Method I: Agilent 1200 series HPLC, Merck Purospher STAR (RP-18e, 30x4 mm) column using 
a flow rate of 1.5 mL/min in a 4 minute gradient elution. Gradient elution was as follows: 10:90 
(A/B) to 90:10 (A/B) over 2.5 min, 90:10 (A/B) for 1 min, and then reversion back to 10:90 
(A/B) over 0.3 min, finally 10:90 (A/B) for 0.2 min. Method II: Agilent 1200 series HPLC, 
Merck Chromolith Flash column (RP-18e, 25 x 2 mm) at 30 °C using a flow rate of 0.75 mL/min 
in a 4 minute gradient elution. Gradient elution was as follows: 5:95 (A/B) to 100:0 (A/B) over 
2.5 min, 100:0 (A/B) for 1 min, and then reversion back to 5:95 (A/B) over 0.1 min, finally 5:95 
(A/B) for 0.4 min. Method III: Waters Acquity UPLC, Phenomenex Kinetex XB-C18 column 
(30 x 2.1 mm, 1.7u, 100A) at 30 °C using flow rate of 0.3 mL/min in a 4 minute gradient elution. 
Gradient elution was as follows: 10:90 (A/B) to 90:10 (A/B) over 3 min, 90:10 (A/B) for 0.5 
min, and then reversion back to 10:90 (A/B) over 0.3 min, finally 10:90 (A/B) for 0.2 min; 
Method IV: Waters Acquity UPLC, Phenomenex Kinetex C18 column (30 x 2.1 mm, 2.6u, 
100A), flow rate and gradient elution according to Method III.  The following reference masses 
were used for HRMS analysis: Agilent 1200 series: caffeine [M + H]+ 195.087652; 
hexakis(1H,1H,3H-tetrafluoropentoxy)phosphazene [M + H]+ 922.009798 and hexakis(2,2-
difluoroethoxy)phosphazene [M + H]+ 622.02896 or reserpine [M + H]+ 609.280657; Waters 
Acquity UPLC: Leucine Enkephalin fragment ion [M + H]+ 397.1876. All compounds were >95 
% purity by LCMS analysis unless otherwise stated. 
General synthetic procedures: 
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Method A: Oxalyl chloride (1.2-1.7 eq.) was added dropwise to a solution of the carboxylic 
acid (1.0-1.5 eq.) and DMF in anhydrous dichloromethane. The reaction mixture was stirred at 
room temperature for three to four hours, and then concentrated. The remaining residue was re-
dissolved in dichloromethane and concentrated again. Then, the aniline (1.0 eq.) was added to 
the remaining residue and the combined solids were dissolved in anhydrous pyridine or a mixture 
of anhydrous pyridine and dichloromethane. The resulting reaction mixture was stirred at room 
temperature overnight. 
Method B: 1-[Bis(dimethylamino)methylene]-1H-1,2,3-triazolo[4,5-b]pyridinium 3-oxid 
hexafluorophosphate (HATU, 1.2-1.3 eq.) was added to a solution of the carboxylic acid (1.0-1.2 
eq.) and N,N-diisopropylethylamine (2.0-5.0 eq.) in anhydrous DMF. The reaction mixture was 
stirred for 10 min, before the aniline (1.0 eq.) was added. The reaction mixture was stirred at 
room temperature overnight. The reaction mixture was then diluted with water. The resulting 
precipitate was isolated by filtration and washed with water. 
Method C: The (3-nitrophenyl)amide (1.0 eq.), iron powder (9-11 eq.), and ammonium 
chloride (9-11 eq.) in ethanol/ water (4/1) were added to a round bottom flask and heated to 
reflux overnight. Then, the reaction mixture was filtered over a short pad of Celite® or silica gel. 
The filtrate was reduced in vacuo until dryness. The remaining residue was re-suspended in 
dichloromethane and washed with sat. NaHCO3 (aq.), water and brine. The organic layer was 
dried over sodium sulfate or magnesium sulfate and reduced in vacuo until dryness to afford the 
corresponding (3-aminophenyl)amide. 
Method D: Palladium (10 % on activated carbon, 42-68 mg/1 mmol) was added to a 
suspension of the nitro compound in a 1:1 mixture of ethanol/ethyl acetate and stirred under H2 
(1 atm.) at 28 ºC overnight. The reaction mixture was then filtered through Celite® and the 
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Celite® pad washed with further ethyl acetate. The filtrate was concentrated in vacuo to afford 
the corresponding aniline. 
Method E: NaH (60 % in mineral oil, 1.1-2.2 eq.) was added to a solution of the alcohol (1.2-
2.8 eq.) in anhydrous THF at 0 ºC. The reaction was allowed to stir at 0 ºC for 10 min, then at 
room temperature for 30 min. 6-Bromo-2-chloroquinoline was added and the resulting 
suspension heated to reflux for 1-16 h. The reaction was allowed to cool to room temperature, 
then diluted with water/sat. NaHCO3 (aq.) and extracted with dichloromethane (3x). The organic 
layers were combined, washed with water, dried over magnesium sulfate and concentrated in 
vacuo to afford the crude product. 
Method F: n-BuLi (1.2-2.2 eq., 2.5 M in hexanes, freshly titrated before use using standard 
procedures) was added dropwise to a solution of the aryl bromide in anhydrous THF at -78 ºC 
under nitrogen. The reaction was stirred at -78 ºC for 40 min, before solid CO2 was added. After 
stirring for 5 min, the reaction was allowed to warm to room temperature. The reaction was 
quenched with water and concentrated under reduced pressure to remove the THF. The aqueous 
layer was washed with ethyl acetate, acidified to pH 3 by the addition of 2M HCl (aq.) and 
concentrated in vacuo to afford the crude product. 
Preparation of compounds in Table 1: 
2-Methyl-N-(2-methyl-5-nitrophenyl)quinoline-6-carboxamide 4 
2-Methylquinoline-6-carboxylic acid 3 (3.69 g, 19.72 mmol), oxalyl chloride (1.8 mL, 20.15 
mmol) and DMF (310 µL, 4.00 mmol) in anhydrous dichloromethane (35 mL) were reacted 
according to method A. 2-Methyl-5-nitroaniline 2 (3.0 g, 19.72 mmol) and the acid chloride were 
then reacted in anhydrous pyridine (35 mL). The reaction mixture was reduced in vacuo until 
dryness. The remaining residue was triturated with diethyl ether. The crude product was purified 
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by column chromatography (Biotage, gradient of 0-50 % ethanol in dichloromethane) to afford 
the product as a yellow amorphous solid (5.57 g, 88 %). IR (thin film): νmax 1661, 1527, 1342, 
1260 cm-1. 1H NMR (500 MHz, DMSO-d6) δ 10.36 (s, 1H), 8.63 (d, J = 1.8 Hz, 1H), 8.43 (d, J 
= 8.4 Hz, 1H), 8.40 (d, J = 2.4 Hz, 1H), 8.25 (dd, J = 8.7, 2.0 Hz, 1H), 8.07 (d, J = 2.9 Hz, 1H), 
8.05 (d, J = 3.0 Hz, 1H), 7.60 (d, J = 8.5 Hz, 1H), 7.54 (d, J = 8.4 Hz, 1H), 2.71 (s, 3H), 2.44 (s, 
3H). 13C NMR (126 MHz, DMSO-d6) δ 165.54, 161.05, 146.20, 144.90, 143.38, 142.15, 137.76, 
132.04, 130.08, 129.93, 129.31, 126.62, 126.09, 124.16, 121.00, 120.94, 23.98, 18.82. HRMS 
(ESI+): calcd for C18H15NaN3O3 (M + Na)
+, 344.1006; found 344.0999. 
N-(5-amino-2-methylphenyl)-2-methylquinoline-6-carboxamide 5 
2-Methyl-N-(2-methyl-5-nitrophenyl)quinoline-6-carboxamide 4 (4.0 g, 12.45 mmol), iron 
powder (6.95 g, 124.0 mmol) and ammonium chloride (2.12 g, 124.0 mmol) in ethanol (50 mL) 
and water (12.5 mL) were reacted according to method C to afford the product as a light yellow 
amorphous solid (1.95 g, 54 %). IR (thin film): νmax 3340, 3252, 1645, 1582, 1487, 1278 cm
-1. 1H 
NMR (500 MHz, DMSO-d6) δ 9.86 (s, 1H), 8.61 – 8.51 (m, 1H), 8.38 (d, J = 8.4 Hz, 1H), 8.21 
(dd, J = 8.8, 1.7 Hz, 1H), 8.00 (d, J = 8.8 Hz, 1H), 7.51 (d, J = 8.4 Hz, 1H), 6.91 (d, J = 8.1 Hz, 
1H), 6.65 (d, J = 2.0 Hz, 1H), 6.42 (dd, J = 8.1, 2.2 Hz, 1H), 4.94 (s, 2H), 2.70 (s, 3H), 2.09 (s, 
3H). 13C NMR (126 MHz, DMSO-d6) δ 165.18, 161.09, 148.86, 147.31, 137.58, 137.01, 132.25, 
130.87, 128.72, 128.49, 128.38, 125.84, 123.38, 120.72, 112.75, 112.61, 25.49, 17.50. HRMS 
(ESI+): calcd for C18H18N3O (M + H)
+, 292.1444; found 292.1446. 
N-(5-(2,3-Dihydrobenzo[b][1,4]dioxine-6-carboxamido)-2-methylphenyl)-2-methylquinoline-
6-carboxamide 1. 
2-Methyl-6-quinolinecarboxylic acid (600 mg, 3.21 mmol), HATU (1.46 g, 3.85 mmol), and 
N-(5-amino-2-methylphenyl)-2-methylquinoline-6-carboxamide 5 (910 mg, 3.21 mmol) were 
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reacted in N,N-diisopropylethylamine (1.12 mL, 6.41 mmol) and anhydrous DMF (25 mL) 
according to method B to afford the product as an off-white amorphous solid (1.38 g, 95 %). IR 
(solid): νmax 2922, 1645, 1582, 1496, 1284, 1258, 1063 cm
-1. 1H NMR (500 MHz, DMSO-d6) δ 
10.14 (s, 1H), 10.08 (s, 1H), 8.61 (s, 1H), 8.41 (br d, J = 7.3 Hz, 1H), 8.24 (d, J = 8.7 Hz, 1H), 
8.03 (d, J = 8.8 Hz, 1H), 7.87 (d, J = 2.1 Hz, 1H), 7.64 – 7.56 (m, 2H), 7.54 (d, J = 2.1 Hz, 1H), 
7.51 (dd, J = 8.4, 2.2 Hz, 1H), 7.24 (d, J = 8.5 Hz, 1H), 6.98 (d, J = 8.4 Hz, 1H), 4.35 – 4.26 (m, 
4H), 2.71 (s, 3H), 2.24 (s, 3H). 13C NMR (126 MHz, DMSO-d6) δ 165.44, 164.82, 161.21, 
148.93, 146.80, 143.39, 137.77, 137.62, 136.74, 131.97, 130.59, 129.23, 128.81, 128.64, 128.38, 
128.14, 125.86, 123.44, 121.66, 119.07, 118.63, 117.30, 117.12, 64.86, 64.48, 25.51, 17.94. 
HRMS (ESI+): calcd for C27H24N3O4 (M + H)
+, 454.1761; found 454.1733. 
N-(5-(2,3-Dihydrobenzo[b][1,4]dioxine-5-carboxamido)-2-methylphenyl)-2-methylquinoline-
6-carboxamide 6. 
2,3-Dihydrobenzo[b][1,4]dioxine-5-carboxylic acid (46 mg, 0.26 mmol), HATU (127 mg, 0.34 
mmol) and N-(5-amino-2-methylphenyl)-2-methylquinoline-6-carboxamide 5 (75 mg, 0.26 
mmol) in N,N-diisopropylethylamine (0.14 mL, 0.82 mmol) and anhydrous DMF (2.5 mL) were 
reacted according to method B to afford the product as a white amorphous solid (95 mg, 81 %). 
IR (solid): νmax 3370, 3256, 1644, 1598, 1532, 1450 1091, 743 cm
-1. 1H NMR (500 MHz, 
DMSO-d6) δ 10.16 (s, 1H), 10.09 (s, 1H), 8.61 (s, 1H), 8.41 (d, J = 8.4 Hz, 1H), 8.27 – 8.21 (m, 
2H), 8.03 (d, J = 8.7 Hz, 1H), 7.82 (br s, 1H), 7.58 – 7.52 (m, 2H), 7.25 (d, J = 8.3 Hz, 1H), 7.18 
– 7.11 (m, 2H), 7.02 – 6.98 (m, 1H), 6.92 (t, J = 7.8 Hz, 1H), 4.40 – 4.27 (m, 4H), 2.71 (s, 3H), 
2.24 (s, 3H). 13C NMR (126 MHz, DMSO-d6) δ 165.43, 164.26, 161.23, 148.94, 144.11, 141.65, 
137.62, 137.52, 136.89, 131.90, 130.74, 129.44, 128.81, 128.67, 128.38, 126.14, 125.85, 123.45, 
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121.73, 121.17, 119.51, 118.44, 118.00, 64.93, 64.21, 25.51, 17.97. HRMS (ESI+): calcd for 
C27H24N3O4 (M + H)
+, 454.1761; found 454.1760. 
N-(5-(3,4-Dimethoxybenzamido)-2-methylphenyl)-2-methylquinoline-6-carboxamide 7. 
3,4-Dimethoxybenzoic acid (34 mg, 0.189 mmol), HATU (82 mg, 0.215 mmol), and N-(5-
amino-2-methylphenyl)-2-methylquinoline-6-carboxamide 5 (50 mg, 0.172 mmol) in N,N-
diisopropylethylamine (0.075 mL, 0.429 mmol) and anhydrous DMF (1.2 mL) were reacted 
according to method B. The crude product was purified by flash column chromatography (1-5 % 
methanol in dichloromethane) to afford compound 7 as a white amorphous solid (52 mg, 67 %). 
IR (thin film): νmax 1648, 1601, 1508, 1418, 1268, 1225 cm
-1. 1H NMR (500 MHz, DMSO-d6) δ 
10.13 (s, 1H), 10.09 (s, 1H), 8.61 (d, J = 2.0 Hz, 1H), 8.41 (d, J = 8.4 Hz, 1H), 8.24 (dd, J = 8.8, 
2.0 Hz, 1H), 8.03 (d, J = 8.8 Hz, 1H), 7.85 (d, J = 2.2 Hz, 1H), 7.62 (td, J = 8.8, 2.2 Hz, 2H), 
7.55 (d, J = 2.1 Hz, 1H), 7.53 (d, J = 8.4 Hz, 1H), 7.26 (d, J = 8.5 Hz, 1H), 7.08 (d, J = 8.5 Hz, 
1H), 3.85 (s, 3H), 3.84 (s, 3H), 2.71 (s, 3H), 2.26 (s, 3H). 13C NMR (126 MHz, DMSO-d6) δ 
165.01, 164.74, 160.76, 151.58, 148.48, 148.26, 137.32, 137.16, 136.27, 131.51, 130.15, 128.75, 
128.37, 128.16, 127.91, 126.92, 125.40, 122.98, 121.03, 118.76, 118.32, 110.98, 110.91, 55.67, 
55.62, 25.04, 17.46. HRMS (ESI+): calcd for C27H26N3O (M + H)
+, 456.19178; found 
456.19189. 
N-(5-(Chroman-7-carboxamido)-2-methylphenyl)-2-methylquinoline-6-carboxamide 8. 
2-Methyl-6-quinolinecarboxylic acid (75 mg, 0.42 mmol), HATU (182 mg, 0.48 mmol) and N-
(5-amino-2-methylphenyl)-2-methylquinoline-6-carboxamide 5 (111 mg, 0.38 mmol) in N,N-
diisopropylethylamine (0.20 mL, 1.15 mmol) and anhydrous DMF (3.5 mL) were reacted 
according to method B. The crude product was purified by column chromatography (Biotage, 
gradient of 0-10 % methanol in dichloromethane) to afford an off-white amorphous solid. This 
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material was triturated with diethyl ether to afford the product as a white amorphous solid (51 
mg, 30 %). IR (thin film): νmax 2957, 1651, 1599, 1527, 1499, 1310, 1283 cm
-1. 1H NMR (500 
MHz, DMSO-d6) δ 10.14 (s, 1H), 10.13 (s, 1H), 8.61 (d, J = 1.8 Hz, 1H), 8.41 (d, J = 8.4 Hz, 
1H), 8.24 (dd, J = 8.8, 1.9 Hz, 1H), 8.03 (d, J = 8.8 Hz, 1H), 7.89 (d, J = 2.0 Hz, 1H), 7.60 (dd, 
J = 8.3, 2.1 Hz, 1H), 7.53 (d, J = 8.4 Hz, 1H), 7.43 (dd, J = 7.9, 1.7 Hz, 1H), 7.36 (d, J = 1.6 
Hz, 1H), 7.25 (d, J = 8.4 Hz, 1H), 7.19 (d, J = 7.9 Hz, 1H), 4.23 – 4.14 (m, 2H), 2.80 (t, J = 6.4 
Hz, 2H), 2.71 (s, 3H), 2.25 (s, 3H), 1.94 (p, J = 6.3 Hz, 2H). 13C NMR (126 MHz, DMSO-d6) δ 
165.44, 165.31, 161.21, 154.79, 148.93, 137.70, 137.63, 136.73, 134.25, 131.96, 130.61, 130.29, 
129.32, 128.81, 128.64, 128.38, 126.70, 125.86, 123.44, 119.61, 119.08, 118.64, 115.94, 66.57, 
25.51, 24.73, 22.00, 17.95. HRMS (ESI+): calcd for C28H26N3O3 (M + H)
+, 452.1969; found 
452.1956. 
N-(5-(Chroman-6-carboxamido)-2-methylphenyl)-2-methylquinoline-6-carboxamide 9. 
Chroman-6-carboxylic acid (40 mg, 0.227 mmol), HATU (98 mg, 0.257 mmol), and N-(5-
amino-2-methylphenyl)-2-methylquinoline-6-carboxamide 5 (60 mg, 0.206 mmol) in N,N-
diisopropylethylamine (0.088 mL, 0.505 mmol) and anhydrous DMF (1.5 mL) were reacted 
according to method B.  The crude product was purified by flash column chromatography (1-3.5 
% methanol in dichloromethane) to afford the product as a white amorphous solid (62 mg, 62 
%). IR (thin film): νmax 1647, 1600, 1528, 1495, 1318, 1256 cm
-1
  
1H NMR (500 MHz, DMSO-
d6) δ 10.13 (s, 1H), 10.04 (s, 1H), 8.61 (d, J = 2.0 Hz, 1H), 8.41 (d, J = 8.4 Hz, 1H), 8.24 (dd, J 
= 8.7, 2.0 Hz, 1H), 8.03 (d, J = 8.7 Hz, 1H), 7.87 (d, J = 2.2 Hz, 1H), 7.75 (d, J = 2.3 Hz, 1H), 
7.72 (dd, J = 8.5, 2.3 Hz, 1H), 7.59 (dd, J = 8.3, 2.2 Hz, 1H), 7.53 (d, J = 8.4 Hz, 1H), 7.24 (d, J 
= 8.6 Hz, 1H), 6.84 (d, J = 8.5 Hz, 1H), 4.23 – 4.17 (m, 2H), 2.82 (t, J = 6.4 Hz, 2H), 2.71 (s, 
3H), 2.24 (s, 3H), 2.00 – 1.91 (m, 2H). 13C NMR (126 MHz, DMSO-d6) δ 164.98, 164.86, 
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160.75, 157.36, 148.47, 137.46, 137.16, 136.25, 131.51, 130.12, 129.78, 128.63, 128.36, 128.17, 
127.91, 127.00, 126.26, 125.40, 122.98, 122.03, 118.54, 118.11, 116.07, 66.36, 25.05, 24.26, 
21.54, 17.47. HRMS (ESI+): calcd for C28H26N3O (M + H)
+, 452.19687; found 452.19758. 
N-(5-(Isochroman-7-carboxamido)-2-methylphenyl)-2-methylquinoline-6-carboxamide 10. 
7-Bromoisochroman (152 mg, 0.71 mmol), Herrmann’s palladacycle (33.4 mg, 0.04 mmol) 
and tri-tert-butylphosphonium tetrafluoroborate (41 mg, 0.14 mmol) were combined with 2-
(trimethylsilyl)ethanol (7.0 mL) in a microwave vial. Molybdenum hexacarbonyl (377 mg, 1.427 
mmol) was then added, followed by DBU (1.0M in THF, 2.57 mL, 2.57 mmol) and the vial 
promptly sealed. The reaction mixture was heated to 130 ºC for 1 h in a microwave. After this 
time further 2-(trimethylsilyl)ethanol (3.0 mL) was added and the reaction heated to 130 ºC for 1 
h under microwave irradiation. The reaction mixture was concentrated under high vacuum. The 
resulting residue was purified by column chromatography (Biotage, gradient of 0-100 % ethyl 
acetate in cyclohexane) to afford 2-(trimethylsilyl)ethyl isochroman-7-carboxylate compound as 
a yellow oil (108 mg, 54 %). This oil was only 80 % pure but was used directly in the next step.75 
To a stirring solution of 2-(trimethylsilyl)ethyl isochroman-7-carboxylate (105 mg, 0.302 
mmol) in THF (3 mL) at room temperature under argon was dropwise added TBAF 1.0 M in 
THF (0.45 mL, 0.45 mmol). The reaction was allowed to stir at room temperature for 2 h. The 
reaction mixture was then diluted with water (25 mL) and the THF removed in vacuo. The 
aqueous layer was washed with dichloromethane (15 mL). TLC/LCMS showed that there was 
product in both the aqueous and organic layers. Therefore the organic layer was extracted with a 
portion of 1M NaOH (15 mL), followed by water (15 mL). The combined aqueous layers were 
acidified (to ~pH 2) using 1M HCl (aq.) and extracted with dichloromethane (3 x 15 mL). The 
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combined organic layer was concentrated in vacuo to afford isochroman-7-carboxylic acid as a 
colorless amorphous solid. This material was used in the next step without further purification. 
2-Methyl-6-quinolinecarboxylic acid 3 (89 mg, 0.28 mmol), HATU (130 mg, 0.34 mmol) and 
N-(3-amino-4-methylphenyl)-2,3-dihydrobenzo[b][1,4]dioxine-6-carboxamide 5 (54 mg, 0.30 
mmol) in N,N-diisopropylethylamine (0.14 mL, 0.82 mmol) and anhydrous DMF (2.5 mL) were 
reacted according to method B. The crude product was purified by column chromatography 
(Biotage, gradient of 0-5 % methanol in dichloromethane) to afford a pale yellow amorphous 
solid (78 mg, 63 %). IR (thin film): νmax 2965, 1650, 1600, 1528, 1499, 1285 cm
-1. 1H NMR (500 
MHz, DMSO-d6) δ 10.19 (s, 1H), 10.14 (s, 1H), 8.61 (d, J = 2.0 Hz, 1H), 8.41 (d, J = 8.4 Hz, 
1H), 8.24 (dd, J = 8.8, 2.0 Hz, 1H), 8.03 (d, J = 8.8 Hz, 1H), 7.88 (d, J = 2.1 Hz, 1H), 7.78 (dd, 
J = 8.0, 1.8 Hz, 1H), 7.67 – 7.65 (m, 1H), 7.60 (dd, J = 8.3, 2.2 Hz, 1H), 7.53 (d, J = 8.4 Hz, 
1H), 7.29 (d, J = 8.0 Hz, 1H), 7.26 (d, J = 8.6 Hz, 1H), 4.76 (s, 2H), 3.91 (t, J = 5.7 Hz, 2H), 
2.86 (t, J = 5.7 Hz, 2H), 2.71 (s, 3H), 2.25 (s, 3H). 13C NMR (126 MHz, DMSO-d6) δ 165.58, 
165.46, 161.22, 148.91, 137.70, 137.66, 137.49, 136.76, 135.49, 132.87, 131.96, 130.65, 129.34, 
129.26, 128.80, 128.65, 128.40, 125.96, 125.86, 124.37, 123.46, 119.05, 118.63, 67.49, 64.82, 
28.24, 25.50, 17.95. HRMS (ESI+): calcd for C28H26N3O3 (M + H)
+, 452.1969; found 452.1964. 
N-(3-(2,3-Dihydrobenzo[b][1,4]dioxine-6-carboxamido)-2,6-dimethylphenyl)-2-
methylquinoline-6-carboxamide 11.  
2,6-Dimethylaniline (4.07 mL, 32.7 mmol) and sulfuric acid (30 mL) were added to a round 
bottom flask. The solution was cooled on an ice bath and nitric acid (2.6 mL, 43.1 mmol, 69 %) 
was added dropwise to the stirred solution. The resulting reaction mixture was warmed to room 
temperature and stirred for further 30 min at room temperature. The reaction mixture was then 
poured onto cold water and neutralized by addition of amorphous solid sodium hydroxide. 2,6-
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dimethyl-3-nitroaniline was isolated by filtration and washed with copious amounts of water.  
The crude product was purified by column chromatography (Biotage, gradient of 0- 40 % ethyl 
acetate in cyclohexane) to afford the product as a brown amorphous solid (1.82 g, 33 %). IR 
(solid): νmax 3421, 3349, 2919, 1634, 1513, 1460, 1348 cm
-1. 1H NMR (500 MHz, DMSO-d6) δ 
6.99 (d, J = 8.1 Hz, 1H), 6.93 (d, J = 8.1 Hz, 1H), 5.21 (s, 2H), 2.15 (s, 3H), 2.14 (s, 3H). 13C 
NMR (126 MHz, DMSO-d6) δ 150.03, 146.44, 127.90, 126.09, 113.71, 111.03, 18.71, 13.41. 
HRMS (ESI+): calcd for C8H11N2O2 (M + H)
+, 167.0815; found 167.0831. 
2-Methylquinoline-6-carboxylic acid 3 (1.27 g, 6.77 mmol), oxalyl chloride (750 µL, 8.40 
mmol) and DMF (110 µL, 1.42 mmol) in anhydrous dichloromethane (15 mL) were reacted 
according to method A. The resulting acid chloride and 2,6-dimethyl-3-nitroaniline (1.5 g, 3.01 
mmol) were then reacted in anhydrous pyridine (20 mL). The reaction mixture was concentrated 
in vacuo. The remaining residue was re-dissolved in dichloromethane and washed with sat. 
NaHCO3 (aq.), water, and brine. The organic layer was dried over sodium sulfate and reduced in 
vacuo until dryness to afford N-(2,6-dimethyl-3-nitrophenyl)-2-methylquinoline-6-carboxamide 
as a dark red to brown amorphous solid (1.69 g). The crude product was used in the next 
synthetic step without further purification. 
N-(2,6-Dimethyl-3-nitrophenyl)-2-methylquinoline-6-carboxamide (1.50 g, 4.47 mmol), iron 
powder (2.50 g, 44.7 mmol), and ammonium chloride (762 mg, 44.7 mmol) in ethanol (40 mL) 
and water (10 mL) were reacted according to method C.  The crude product was purified by 
column chromatography (Biotage, gradient 0-30 % ethanol in dichloromethane) to afford the 
product as a brown amorphous solid (1.14 g, 84 %). IR (solid): νmax 3232, 2916, 1649, 1621, 
1487, 1281 cm-1. 1H NMR (500 MHz, DMSO-d6) δ 9.84 (s, 1H), 8.60 (d, J = 1.9 Hz, 1H), 8.39 
(d, J = 8.4 Hz, 1H), 8.25 (dd, J = 8.8, 2.0 Hz, 1H), 8.01 (d, J = 8.7 Hz, 1H), 7.51 (d, J = 8.4 Hz, 
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1H), 6.82 (d, J = 8.1 Hz, 1H), 6.56 (d, J = 8.1 Hz, 1H), 4.72 (s, 2H), 2.70 (s, 3H), 2.07 (s, 3H), 
1.95 (s, 3H). 13C NMR (126 MHz, DMSO-d6) δ 165.08, 161.05, 148.86, 145.57, 137.57, 135.64, 
132.08, 128.77, 128.40, 128.27, 127.51, 125.89, 123.38, 123.09, 120.01, 113.46, 25.49, 18.15, 
12.84. HRMS (ESI+): calcd for C19H20N3O (M + H)
+, 306.1606; found 306.1597. 
2,3-Dihydrobenzo[b][1,4]dioxine-6-carboxylic acid (415 mg, 2.30 mmol), oxalyl chloride (350 
µL, 3.92 mmol) and DMF (50 µL, 646 mmol) in anhydrous dichloromethane (10 mL) were 
reacted according to method A. N-(3-Amino-2,6-dimethylphenyl)-2-methylquinoline-6-
carboxamide (703 mg, 2.30 mmol) and the acid chloride were then reacted in anhydrous 
pyridine. The reaction mixture was diluted with diethyl ether. The product precipitated from the 
solution, was isolated by filtration and washed with water and diethyl ether. The crude product 
was purified by column chromatography (Biotage, gradient of 0-10 % ethanol in 
dichloromethane) to afford compound 11 as a beige amorphous solid (237.4 mg, 22 %). IR (thin 
film): νmax 1649, 1584, 1487, 1290, 1067 cm
-1. 1H NMR (500 MHz, DMSO-d6) δ 10.08 (s, 1H), 
9.80 (s, 1H), 8.63 (s, 1H), 8.41 (d, J = 8.4 Hz, 1H), 8.27 (d, J = 10.8 Hz, 1H), 8.04 (d, J = 8.8 
Hz, 1H), 7.55 (d, J = 2.0 Hz, 1H), 7.54 – 7.53 (m, 1H), 7.53 – 7.50 (m, 1H), 7.18 (m, 2H), 6.98 
(d, J = 8.4 Hz, 1H), 4.32 – 4.29 (m, 4H), 2.71 (s, 3H), 2.24 (s, 3H), 2.10 (s, 3H). 13C NMR (126 
MHz, DMSO-d6) δ 165.22, 164.92, 161.17, 148.93, 146.73, 143.41, 137.60, 136.13, 135.30, 
133.96, 132.95, 131.78, 128.86, 128.55, 128.27, 127.84, 127.38, 126.24, 125.90, 123.44, 121.61, 
117.31, 117.12, 64.85, 64.47, 25.51, 18.59, 13.94. HRMS (ESI+): calcd for C28H26N3O4 (M + 
H)+, 468.1923; found 428.1932. 
N-(5-(2,3-Dihydrobenzo[b][1,4]dioxine-6-carboxamido)-2,4-dimethylphenyl)-2-
methylquinoline-6-carboxamide 12. 
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2,3-Dihydrobenzo[b][1,4]dioxine-6-carboxylic acid (542 mg, 3.01 mmol), oxalyl chloride (325 
µL, 4.71 mmol) and DMF (50 µL, 0.646 mmol) in anhydrous dichloromethane (10 mL) were 
reacted according to method A. 2,4-Dimethyl-5-nitroaniline (500 mg, 3.01 mmol) and the acid 
chloride were then reacted in anhydrous pyridine (15 mL). The reaction mixture was 
concentrated in vacuo. The remaining residue was triturated with diethyl ether and dried in vacuo 
to give N-(2,4-dimethyl-5-nitrophenyl)-2,3-dihydrobenzo[b][1,4]dioxine-6-carboxamide as a 
brown amorphous solid (1.11 g), which was used in the next synthetic step without further 
purification. 
N-(2,4-Dimethyl-5-nitrophenyl)-2,3-dihydrobenzo[b][1,4]dioxine-6-carboxamide (988 mg, 
2.08 mmol), ammonium chloride (394 mg, 23.1 mmol) and iron powder (1.29 g, 23.1 mmol) in 
ethanol (10 mL) and water (2.5 mL) were reacted according to method C to afford N-(5-amino-
2,4-dimethylphenyl)-2,3-dihydrobenz[b][1,4]dioxine-6-carboxamide as a brown amorphous solid 
(353 mg, 57 % over two steps). IR (solid): νmax 3352, 3265, 2918, 1634, 1613, 1489, 1288 cm
-1. 
1H NMR (500 MHz, DMSO-d6) δ 9.43 (s, 1H), 7.49 (d, J = 2.0 Hz, 1H), 7.47 (dd, J = 8.3, 2.1 
Hz, 1H), 6.95 (d, J = 8.3 Hz, 1H), 6.77 (s, 1H), 6.58 (s, 1H), 4.65 (s, 2H), 4.40 – 4.10 (m, 4H), 
2.02 (s, 3H), 2.00 (s, 3H). 13C NMR (126 MHz, DMSO-d6) δ 164.53, 146.53, 144.85, 143.36, 
134.81, 131.82, 128.22, 121.45, 121.11, 119.64, 117.23, 117.00, 113.13, 64.81, 64.46, 17.41, 
17.29. HRMS (ESI+): calcd for C17H19N2O3 (M + H)
+, 299.1396; found 299.1555. 
2-Methylquinoline-6-carboxylic acid 3 (188 mg, 1.00 mmol), oxalyl chloride (80 µL, 0.896 
mmol) and DMF (20 µL, 0.258 mmol) in anhydrous dichloromethane (5 mL) were reacted 
according to method A. The resulting acid chloride and N-(5-amino-2,4-dimethylphenyl)-2,3-
dihydrobenz[b][1,4]dioxine-6-carboxamide (201 mg, 0.674 mmol) were then reacted in 
anhydrous pyridine (10 mL). The reaction mixture was then diluted with dichloromethane and 
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washed with sat. NaHCO3 (aq.), water and brine. The organic layer was dried over sodium 
sulfate and reduced in vacuo until dryness. The crude product was purified by column 
chromatography (Biotage, gradient of 0-5 % ethanol in dichloromethane). The product was 
further purified by semi-preparative HPLC, according to the method specified in the general 
procedures, to afford a beige amorphous solid (30.4 mg, 9.7 %). IR (solid): νmax 1664, 1620, 
1531, 1497, 1291 cm-1. 1H NMR (500 MHz, DMSO-d6) δ 10.09 (s, 1H), 9.71 (s, 1H), 8.59 (s, 
1H), 8.40 (d, J = 8.4 Hz, 1H), 8.29 – 8.16 (m, 1H), 8.02 (d, J = 8.8 Hz, 1H), 7.64 – 7.43 (m, 3H), 
7.35 (s, 1H), 7.17 (s, 1H), 6.98 (d, J = 8.3 Hz, 1H), 4.39 – 4.15 (m, 4H), 2.70 (s, 3H), 2.25 (s, 
3H), 2.20 (s, 3H). 13C NMR (126 MHz, DMSO-d6) δ 165.48, 164.83, 161.18, 148.91, 146.74, 
143.41, 137.60, 134.65, 134.46, 132.25, 132.01, 131.85, 131.63, 128.77, 128.61, 128.40, 127.87, 
125.84, 125.00, 123.43, 121.60, 117.31, 117.11, 64.84, 64.48, 25.50, 17.97, 17.89. HRMS 
(ESI+): calcd for C28H26N3O4 (M + H)
+, 468.1923; found 468.1914. 
2-Methyl-N-(2-methyl-5-(N-methyl-2,3-dihydrobenzo[b][1,4]dioxine-6-
carboxamido)phenyl)quinolone-6-carboxamide 13. 
4-Methyl-3-nitroaniline 2 (5.15 g, 33.8 mmol) was dissolved in DMF (20 mL) and 
iodomethane (1.8 mL, 28.9 mmol) was added. Then, sat. NaHCO3 (aq.) (20 mL, 28.2 mmol) was 
added portionwise to the stirred reaction mixture. The resulting reaction mixture was stirred at 
room temperature overnight. The reaction mixture was partitioned between dichloromethane and 
water. The aqueous layer was extracted with dichloromethane. The combined organic layers 
were then washed with water and brine. The crude product was purified by column 
chromatography (Biotage, gradient of 0-20 % ethyl acetate in cyclohexane) to afford N,4-
dimethyl-3-nitroaniline as a red amorphous solid (1.55 g, 33 % yield). IR (thin film): νmax 3401, 
2926, 1690, 1526, 1493, 1321, 1286 cm-1. 1H NMR (500 MHz, CDCl3) δ 7.18 (d, J = 2.6 Hz, 
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1H), 7.10 (d, J = 8.3 Hz, 1H), 6.75 (dd, J = 8.3, 2.6 Hz, 1H), 3.91 (s, 1H), 2.87 (s, 3H), 2.47 (s, 
3H). 13C NMR (126 MHz, CDCl3) δ 149.77, 148.06, 133.16, 121.34, 117.63, 106.97, 30.65, 
19.53. HRMS (ESI+): calcd for C8H11N2O2 (M + H)
+, 167.0820; found 167.0825. 
2,3-Dihydrobenzo[b][1,4]dioxine-6-carboxylic acid (1.63 g, 9.03 mmol), oxalyl chloride (970 
µL, 10.86 mmol) and DMF (140 µL, 1.81 mmol) in anhydrous dichloromethane (15 mL) were 
reacted according to method A. The resulting acid chloride and N-4-Dimethyl-3-nitroaniline (1.5 
g, 9.03 mmol) were then reacted in anhydrous dichloromethane (15 mL) and pyridine (3.0 mL, 
34.0 mmol). The reaction mixture was diluted with dichloromethane and washed with sat. NH4Cl 
(aq.). The aqueous layer was extracted with dichloromethane. The combined organic layers were 
washed with sat. NH4Cl (aq.), water, and brine. The organic layer was dried over sodium sulfate 
and reduced in vacuum until dryness to give N-Methyl-N-(4-methyl-3-nitrophenyl)-2,3-
dihydrobenz[b][1,4]dioxine-6-carboxamide (2.51 g), which was used in the next synthetic step 
without further purification. 
N-Methyl-N-(4-methyl-3-nitrophenyl)-2,3-dihydrobenz[b][1,4]dioxine-6-carboxamide (2.50 g, 
7.61 mmol), iron powder (4.56 g, 82.0 mmol) and ammonium chloride (1.36 g, 80 mmol) in 
ethanol (20 mL) and water (5 mL) were reacted according to method C. The crude product was 
re-suspended in water. The product was isolated by filtration and washed with water and diethyl 
ether. The product was isolated as a beige amorphous solid (1.18 g, 52 %). IR (solid): νmax 3447, 
3354, 2934, 1600, 1579, 1509, 1426, 1282 cm-1. 1H NMR (500 MHz, DMSO-d6) δ 6.85 – 6.82 
(m, 1H), 6.80 (d, J = 7.8 Hz, 1H), 6.78 – 6.72 (m, 1H), 6.66 (d, J = 8.4 Hz, 1H), 6.40 – 6.32 (m, 
1H), 6.23 – 6.13 (m, 1H), 4.92 (s, 2H), 4.18 (d, J = 8.0 Hz, 4H), 3.23 (s, 3H), 1.97 (s, 3H). 13C 
NMR (126 MHz, DMSO-d6) δ 168.76, 147.70, 144.89, 144.04, 142.72, 130.83, 129.67, 122.40, 
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119.85, 118.09, 116.54, 114.85, 112.22, 64.58, 64.32, 38.98, 17.45. HRMS (ESI+): calcd for 
C17H19N2O3 (M + H)
+, 300.1474; found 299.1401. 
2-Methylquinoline-6-carboxylic acid 3 (345 mg, 1.84 mmol), oxalyl chloride (180 µL, 2.06 
mmol) and DMF (300 µL, 3.87 mmol) in anhydrous dichloromethane (10 mL) were reacted 
according to method A. The resulting acid chloride and N-(3-amino-4-methylphenyl)-N-methyl-
2,3-dihydrobenzo[b][1,4]dioxine-6-carboxamide (500 mg, 1.68 mmol) were then reacted in 
anhydrous dichloromethane (13 mL) and pyridine (1.2 mL, 14.89 mmol). The reaction mixture 
was diluted with water. The product was isolated by filtration and washed with water and diethyl 
ether.  The crude product was then purified with a cation exchange sorbent (Isolute SCX-II, 
washing first with methanol, and then with 10 % 2 M ammonia in methanol). The product was 
further purified by semi-preparative HPLC according to the method specified in the general 
procedures to afford a yellow amorphous solid (22.4 mg, 2.9 %). IR (solid): νmax 2927, 1624, 
1493, 1282 cm-1. 1H NMR (500 MHz, DMSO-d6) δ 10.09 (s, 1H), 8.59 (d, J = 1.8 Hz, 1H), 8.39 
(d, J = 8.4 Hz, 1H), 8.21 (dd, J = 8.8, 1.9 Hz, 1H), 8.02 (d, J = 8.8 Hz, 1H), 7.52 (d, J = 8.4 Hz, 
1H), 7.36 (d, J = 2.2 Hz, 1H), 7.18 (d, J = 8.2 Hz, 1H), 6.90 (dd, J = 8.1, 2.2 Hz, 1H), 6.87 (d, J 
= 2.0 Hz, 1H), 6.76 (d, J = 2.0 Hz, 1H), 6.68 (d, J = 8.4 Hz, 1H), 4.27 – 4.14 (m, 4H), 3.17 (s, 
3H), 2.70 (s, 3H), 2.23 (s, 3H). 13C NMR (126 MHz, DMSO-d6) δ 169.06, 161.29, 148.95, 
144.99, 143.28, 142.94, 137.62, 137.39, 131.93, 131.75, 131.25, 129.44, 128.80, 128.75, 128.39, 
125.81, 125.05, 124.52, 123.47, 122.42, 118.16, 116.71, 64.60, 64.33, 49.06, 38.94, 25.51, 18.04. 
HRMS (ESI+): calcd for C28H26N3O4 (M + H)
+, 468.1923; found 468.1919. 
N-(5-(2,3-Dihydrobenzo[b][1,4]dioxine-6-sulfonamido)-2-methylphenyl)-2-methylquinoline-
6-carboxamide 14  
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2-Methylquinoline-6-carboxylic acid (3.69 g, 19.72 mmol), oxalyl chloride (1.8 mL, 20.15 
mmol) and DMF (310 µL, 4.00 mmol) were reacted in anhydrous dichloromethane (35 mL) 
according to method A. The resulting acid chloride was reacted with 2-methyl-5-nitroaniline (3.0 
g, 19.72 mmol) in anhydrous pyridine (35 mL). The reaction mixture was reduced in vacuo until 
dryness. The remaining residue was triturated with diethyl ether and dried in vacuo. The crude 
product was purified by column chromatography (Biotage, gradient of 0-50 % ethanol in 
dichloromethane) to afford the product as a yellow amorphous solid (5.57 g, 88 %). IR (thin 
film): νmax 1661, 1527, 1342, 1260 cm
-1. 1H NMR (500 MHz, DMSO-d6) δ 10.36 (s, 1H), 8.63 
(d, J = 1.8 Hz, 1H), 8.43 (d, J = 8.4 Hz, 1H), 8.40 (d, J = 2.4 Hz, 1H), 8.25 (dd, J = 8.7, 2.0 Hz, 
1H), 8.07 (d, J = 2.9 Hz, 1H), 8.05 (d, J = 3.0 Hz, 1H), 7.60 (d, J = 8.5 Hz, 1H), 7.54 (d, J = 8.4 
Hz, 1H), 2.71 (s, 3H), 2.44 (s, 3H). 13C NMR (126 MHz, DMSO-d6) δ 165.54, 161.05, 146.20, 
144.90, 143.38, 142.15, 137.76, 132.04, 130.08, 129.93, 129.31, 126.62, 126.09, 124.16, 121.00, 
120.94, 23.98, 18.82. HRMS (ESI+): calcd for C18H15NaN3O3 (M + Na)
+, 344.1006; found 
344.0999. 
2-Methyl-N-(2-methyl-5-nitrophenyl)quinoline-6-carboxamide (4.0 g, 12.45 mmol), iron 
powder (6.95 g, 124.0 mmol), and ammonium chloride (2.12 g, 124.0 mmol) in ethanol (50 mL) 
and water (12.5 mL) were reacted according to method C to afford N-(5-amino-2-methylphenyl)-
2-methylquinoline-6-carboxamide as a light yellow amorphous solid (1.95 g, 48 % over two 
steps). IR (thin film): νmax 3340, 3252, 1645, 1582, 1487, 1278 cm
-1. 1H NMR (500 MHz, 
DMSO-d6) δ 9.86 (s, 1H), 8.61 – 8.51 (m, 1H), 8.38 (d, J = 8.4 Hz, 1H), 8.21 (dd, J = 8.8, 1.7 
Hz, 1H), 8.00 (d, J = 8.8 Hz, 1H), 7.51 (d, J = 8.4 Hz, 1H), 6.91 (d, J = 8.1 Hz, 1H), 6.65 (d, J = 
2.0 Hz, 1H), 6.42 (dd, J = 8.1, 2.2 Hz, 1H), 4.94 (s, 2H), 2.70 (s, 3H), 2.09 (s, 3H). 13C NMR 
(126 MHz, DMSO-d6) δ 165.18, 161.09, 148.86, 147.31, 137.58, 137.01, 132.25, 130.87, 128.72, 
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128.49, 128.38, 125.84, 123.38, 120.72, 112.75, 112.61, 25.49, 17.50. HRMS (ESI+): calcd for 
C18H18N3O (M + H)
+, 292.1444; found 292.1446. 
N-(5-Amino-2-methylphenyl)-2-methylquinoline-6-carboxamide (500 mg, 1.60 mmol) and 
2,3-dihydrobenzo[b][1,4]dioxine-6-sulfonyl chloride (591 mg, 2.39 mmol) and anhydrous 
pyridine (7 mL) were added to a round bottom flask. The resulting reaction mixture was stirred 
at room temperature under argon overnight. The reaction mixture was diluted with diethyl ether. 
The product was isolated by filtration and washed with water and diethyl ether. The crude 
product was purified by column chromatography (Biotage, gradient of 0-10 % ethanol in 
dichloromethane) to afford the product as a beige amorphous solid (90.7 mg, 12 %). IR (thin 
film): νmax 1651, 1529, 1494, 1328, 1285, 1254, 1153 cm
-1. 1H NMR (500 MHz, DMSO-d6) δ 
10.14 (s, 1H), 10.06 (s, 1H), 8.57 (d, J = 1.9 Hz, 1H), 8.40 (d, J = 8.4 Hz, 1H), 8.20 (dd, J = 8.8, 
2.0 Hz, 1H), 8.01 (d, J = 8.8 Hz, 1H), 7.52 (d, J = 8.4 Hz, 1H), 7.30 – 7.23 (m, 2H), 7.22 (d, J = 
2.2 Hz, 1H), 7.14 (d, J = 8.4 Hz, 1H), 6.99 (d, J = 8.4 Hz, 1H), 6.94 (dd, J = 8.2, 2.2 Hz, 1H), 
4.53 – 3.98 (m, 4H), 2.70 (s, 3H), 2.16 (s, 3H). 13C NMR (126 MHz, DMSO-d6) δ 165.30, 
161.25, 147.61, 143.69, 137.73, 137.72, 137.30, 136.26, 132.43, 131.78, 131.30, 129.59, 128.75, 
128.72, 128.41, 125.83, 123.47, 120.81, 118.35, 118.00, 117.84, 116.11, 64.80, 64.48, 25.46, 
17.83. HRMS (ESI+): calcd for C26H24N3O5S (M + H)
+, 490.1436; found 490.1436. 
N-(5-(2,3-Dihydrobenzo[b][1,4]dioxine-6-carboxamido)-2-methylphenyl)quinoline-6-
carboxamide 15 
6-Quinolinecarboxylic acid (0.064 g, 0.369 mmol), HATU (0.160 g, 0.422 mmol), and N-(3-
amino-4-methylphenyl)-2,3-dihydrobenzo[b][1,4]dioxine-6-carboxamide 18 (0.100 g, 0.352 
mmol) in N,N-Diisopropylethylamine (0.123 mL, 0.703 mmol) and anhydrous DMF (2.5 mL) 
were reacted according to method B to afford a white amorphous solid (141 mg, 91 %). IR (thin 
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film): νmax 1649, 1599, 1528, 1504, 1318, 1290, 1260, 1066 cm
-1. 1H NMR (500 MHz, DMSO-
d6) δ 10.18 (s, 1H), 10.08 (s, 1H), 9.02 (dd, J = 4.2, 1.9 Hz, 1H), 8.67 (d, J = 1.9 Hz, 1H), 8.55 
(dd, J = 8.5, 1.9 Hz, 1H), 8.29 (dd, J = 8.8, 2.2 Hz, 1H), 8.15 (d, J = 8.8 Hz, 1H), 7.88 (d, J = 
2.1 Hz, 1H), 7.65 (dd, J = 9.6, 2.2 Hz, 1H), 7.59 (dd, J = 8.5, 2.2 Hz, 1H), 7.54 (d, J = 2.2 Hz, 
1H), 7.51 (dd, J = 8.5, 2.2 Hz, 1H), 7.25 (d, J = 8.5 Hz, 1H), 6.99 (d, J = 8.5 Hz, 1H), 4.33 – 
4.29 (m, 4H), 2.25 (s, 3H). 13C NMR (126 MHz, DMSO-d6) δ 165.38, 164.83, 152.68, 149.25, 
146.82, 143.40, 137.80, 137.67, 136.67, 132.83, 130.63, 129.61, 129.24, 128.95, 128.47, 128.14, 
127.61, 122.73, 121.67, 119.06, 118.68, 117.31, 117.13, 64.86, 64.49, 17.95. HRMS (ESI+): 
calcd for C26H22N3O4 (M + H)
+, 440.1605; found 440.1768. 
N-(5-(2,3-Dihydrobenzo[b][1,4]dioxine-6-carboxamido)-2-methylphenyl)isoquinoline-7-
carboxamide 16 
Isoquinoline-7-carboxylic acid (50 mg, 0.290 mmol), HATU (130 mg, 0.343 mmol) and N-(3-
amino-4-methylphenyl)-2,3-dihydrobenzo[b][1,4]dioxine-6-carboxamide 18 (75 mg, 0.264 
mmol) in N,N-diisopropylethylamine (0.101 mL, 0.580 mmol) and anhydrous DMF (1.8 mL) 
were reacted according to method B. The crude product was purified by trituration and brief 
sonication in ethyl acetate, then isolated by filtration and washed with ethyl acetate to afford the 
product as a white amorphous solid (52 mg, 45 %). IR (thin film): νmax 1641, 1599, 1531, 1504, 
1319, 1295, 1243, 1065 cm-1. 1H NMR (500 MHz, DMSO-d6) δ 10.23 (s, 1H), 10.08 (s, 1H), 
9.48 (s, 1H), 8.81 (s, 1H), 8.62 (d, J = 5.7 Hz, 1H), 8.30 (dd, J = 8.6, 1.7 Hz, 1H), 8.12 (d, J = 
8.6 Hz, 1H), 7.94 (d, J = 5.7 Hz, 1H), 7.89 (d, J = 2.1 Hz, 1H), 7.59 (dd, J = 8.3, 2.2 Hz, 1H), 
7.54 (d, J = 2.1 Hz, 1H), 7.51 (dd, J = 8.4, 2.2 Hz, 1H), 7.25 (d, J = 8.6 Hz, 1H), 6.98 (d, J = 8.4 
Hz, 1H), 4.32 – 4.29 (m, 4H), 2.25 (s, 3H). 13C NMR (126 MHz, DMSO-d6) δ 165.08, 164.82, 
153.21, 146.81, 143.39, 143.20, 137.80, 137.37, 136.53, 134.19, 130.65, 130.19, 129.23, 128.72, 
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128.11, 127.81, 127.48, 121.65, 121.41, 119.02, 118.74, 117.30, 117.12, 64.85, 64.48, 17.93. 
HRMS (ESI+): calcd for C26H22N3O4 (M + H)
+, 440.1605; found 440.1604. 
N-(5-(2,3-Dihydrobenzo[b][1,4]dioxine-6-carboxamido)-2-methylphenyl)-1,2,3,4-
tetrahydroquinoline-6-carboxamide 17 
A suspension of N-(5-(2,3-dihydrobenzo[b][1,4]dioxine-6-carboxamido)-2 
methylphenyl)quinoline-6-carboxamide 15 (0.097 g, 0.22 mmol) and Pd/C (10 %, 0.025 g) in 
methanol (8 mL), ethyl acetate (6 mL) and 10 drops glacial acetic acid was stirred under 1 atm 
hydrogen at 40°C overnight, filtered through Celite® with ethyl acetate, and concentrated. The 
residue was purified by flash column chromatography using a gradient of 10 to 22 % ethyl 
acetate  in dichloromethane to afford the title compound (72 mg, 74 %) as a white amorphous 
solid. IR (solid): νmax 2924, 1634, 1604, 1579, 1504, 1291, 1248, 1065, 888 cm
-1. 1H NMR (500 
MHz, DMSO-d6) δ 10.02 (s, 1H), 9.35 (s, 1H), 7.77 (d, J = 2.2 Hz, 1H), 7.57 – 7.52 (m, 4H), 
7.50 (dd, J = 8.5, 2.2 Hz, 1H), 7.18 (d, J = 8.4 Hz, 1H), 6.98 (d, J = 8.4 Hz, 1H), 6.47 (d, J = 9.0 
Hz, 1H), 6.35 (br s, 1H), 4.34 – 4.27 (m, 4H), 3.27 – 3.20 (m, 2H), 2.72 (t, J = 6.2 Hz, 2H), 2.17 
(s, 3H), 1.85 – 1.76 (m, 2H). 13C NMR (126 MHz, DMSO-d6) δ 165.65, 164.74, 148.79, 146.76, 
143.38, 137.56, 137.50, 130.31, 129.43, 129.00, 128.21, 127.29, 121.64, 120.44, 119.09, 119.06, 
117.93, 117.28, 117.11, 112.41, 64.85, 64.48, 41.05, 27.27, 21.50, 17.95. HRMS (ESI+): calcd 
for C26H26N3O4 (M + H)
+, 444.1718; found 444.1812. 
N-(3-Amino-4-methylphenyl)-2,3-dihydrobenzo[b][1,4]dioxine-6-carboxamide 18 
1,4-Benzodioxane-6-carboxylic acid (2.486 g, 13.80 mmol), oxalyl chloride (1.40 mL, 16.6 
mmol) and DMF (0.027 mL, 0.34 mmol) in anhydrous dichloromethane (34 mL) were reacted 
according to method A. The resulting acid chloride was dissolved in anhydrous dichloromethane 
(12 mL) and added dropwise to a solution of 4-methyl-3-nitroaniline 2 (2.100 g, 13.80 mmol) 
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and pyridine (2.23 mL, 27.6 mmol) in anhydrous dichloromethane (35 mL). The reaction 
mixture was stirred at room temperature for two hours, and then concentrated. The resulting 
amorphous solid was suspended in methanol, diluted with water and then isolated by filtration 
and washed with water to afford N-(4-methyl-3-nitrophenyl)-2,3-dihydrobenzo[b][1,4]dioxine-6-
carboxamide (4.24 g, 98 %) as a pale tan colored amorphous solid, which was used in the next 
step without further purification. 
Palladium (10 % on activated carbon, 0.567 g) and N-(4-methyl-3-nitrophenyl)-2,3-
dihydrobenzo[b][1,4]dioxine-6-carboxamide (4.237 g, 13.48 mmol) in ethanol (90 mL) and ethyl 
acetate (90 mL) were reacted according to method D to afford the desired product (3.803 g, 99 
%) as a pale yellow amorphous solid. IR (thin film): νmax 1641, 1611, 1582, 1289, 1064 cm
-1. 1H 
NMR (500 MHz, DMSO-d6) δ 9.70 (s, 1H), 7.49 (d, J = 2.2 Hz, 1H), 7.46 (dd, J = 8.3, 2.2 Hz, 
1H), 7.10 (d, J = 2.0 Hz, 1H), 6.95 (d, J = 8.4 Hz, 1H), 6.83 (d, J = 8.1 Hz, 1H), 6.79 (dd, J = 
8.1, 2.0 Hz, 1H), 4.81 (s, 2H), 4.32 – 4.26 (m, 4H), 2.01 (s, 3H). 13C NMR (126 MHz, DMSO-
d6) δ 164.48, 146.89, 146.54, 143.30, 138.09, 130.04, 128.60, 121.54, 117.18, 117.05, 109.26, 
106.88, 64.82, 64.47, 17.46. (1 carbon missing) HRMS (ESI+): calcd for C16H17N2O3 (M + H)
+, 
285.1234; found 285.1233.  
Preparation of compounds in Table 2: 
N-(5-(2,3-Dihydrobenzo[b][1,4]dioxine-6-carboxamido)-2-methylphenyl)-2-(2-
methoxyethoxy)quinoline-6-carboxamide 21 
NaH (60 % in mineral oil, 0.198 g, 4.950 mmol) was added to 2-methoxyethanol (4.0 mL, 50.7 
mmol) at 0 °C under inert atmosphere. The reaction mixture was stirred at 0 °C for 10 min then 
at room temperature for 20 min, before 6-bromo-2-chloroquinoline (0.400 g, 1.649 mmol) was 
added. This suspension was then gradually heated to 70 °C, the amorphous solid dissolved as 
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heated and the resulting solution was allowed to stir overnight. The reaction mixture was cooled 
to room temperature, diluted with water and the resulting precipitate isolated by filtration. The 
precipitate was washed with water and dried to afford 6-bromo-2-(2-methoxyethoxy)quinoline as 
a dull pink amorphous solid (0.497 g), which was used in the next step without further 
purification. 
n-BuLi (1.84 M in hexanes) (0.578 mL, 1.063 mmol) was added dropwise to a solution of 6-
bromo-2-(2-methoxyethoxy)quinoline (0.250 g, 0.886 mmol) in anhydrous THF (3.0 mL) at -
78°C and the resulting brown-yellow mixture was stirred at -78°C for 35 min. Solid CO2 was 
added and the resulting orange mixture was stirred at -78°C for 5 min, then it was allowed to 
warm to room temperature and concentrated under reduced pressure. The residue was dissolved 
in brine (5.0 mL) and washed with dichloromethane (1 x 5.0 mL). The aqueous phase was 
acidified with 2 M HCl (aq.) to pH 3 and the resulting precipitate was isolated by filtration and 
washed with water to afford 2-(2-methoxyethoxy)quinoline-6-carboxylic acid as a pale pink 
amorphous solid (0.127 g), which was used in next step without further purification.  
2-(2-Methoxyethoxy)quinoline-6-carboxylic acid (0.048 g, 0.193 mmol), HATU (0.084 g, 
0.220 mmol), and  N-(3-amino-4-methylphenyl)-2,3-dihydrobenzo[b][1,4]dioxine-6-
carboxamide 18 (0.050 g, 0.176 mmol) in N,N-diisopropylethylamine (0.068 mL, 0.387 mmol) 
and anhydrous DMF (1.25 mL) were reacted according to method B to afford the product 21 as a 
white amorphous solid (87 mg, 56 % over 3 steps). IR (thin film): νmax 2925, 1642, 1602, 1582, 
1526, 1502, 1345, 1286, 1261, 816, 784 cm-1. 1H NMR (500 MHz, DMSO-d6) δ 10.07 (app. d, J 
= 3.0 Hz, 2H), 8.57 (d, J = 2.0 Hz, 1H), 8.39 (d, J = 8.8 Hz, 1H), 8.22 (dd, J = 8.7, 2.0 Hz, 1H), 
7.89 – 7.84 (m, 2H), 7.58 (dd, J = 8.3, 2.2 Hz, 1H), 7.54 (d, J = 2.1 Hz, 1H), 7.51 (dd, J = 8.4, 
2.2 Hz, 1H), 7.24 (d, J = 8.6 Hz, 1H), 7.14 (d, J = 8.8 Hz, 1H), 6.98 (d, J = 8.4 Hz, 1H), 4.61 – 
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4.55 (m, 2H), 4.32– 4.29  (m, 4H), 3.77 – 3.72 (m, 2H), 3.33 (s, 3H), 2.24 (s, 3H). 13C NMR (126 
MHz, DMSO-d6) δ 165.39, 164.81, 163.13, 147.93, 146.80, 143.38, 140.80, 137.75, 136.78, 
130.57, 129.22, 128.90, 128.58, 128.15, 127.21, 126.76, 124.52, 121.65, 119.07, 118.57, 117.29, 
117.12, 114.39, 70.56, 65.40, 64.85, 64.48, 58.58, 17.94. HRMS (ESI+): calcd for C29H28N3O6 
(M + H)+, 514.1973; found 514.1969. 
N-(5-(2,3-Dihydrobenzo[b][1,4]dioxine-6-carboxamido)-2-methylphenyl)-2-(3-
(dimethylamino)propoxy)quinoline-6-carboxamide 22 
NaH (60 % in mineral oil, 0.109 g, 2.72 mmol), 4-(2-hydroxyethyl)morpholine (0.337 mL, 
2.78 mmol), and 6-bromo-2-chloroquinoline (0.3 g, 1.237 mmol) in anhydrous THF (4 mL) were 
reacted according to method E. The reaction mixture was heated for 1 h. The crude product was 
purified by flash column chromatography (4-6 % methanol in dichloromethane) to afford 3-((6-
bromoquinolin-2-yl)oxy)-N,N-dimethylpropan-1-amine as a pale salmon colored oil (0.346 g), 
which was used directly in the next step. 
n-BuLi (1.62 M in hexanes, 0.788 mL, 1.277 mmol) and 3-((6-bromoquinolin-2-yl)oxy)-N,N-
dimethylpropan-1-amine (0.329 g, 1.064 mmol) in anhydrous THF (3.5 mL) were reacted 
according to method F to afford 2-(3-(dimethylamino)propoxy)quinoline-6-carboxylic acid as a 
white amorphous solid (0.170 g), which was used in the next step without further purification. 
2-(3-(Dimethylamino)propoxy)quinoline-6-carboxylic acid (91 mg, 0.220 mmol), HATU (104 
mg, 0.275 mmol) and N-(3-amino-4-methylphenyl)-2,3-dihydrobenzo[b][1,4]dioxine-6-
carboxamide 18 (50 mg, 0.176 mmol) in N,N-diisopropylethylamine (0.154 mL, 0.879 mmol) 
and anhydrous DMF (1.5 mL) were reacted according to method B.  The crude product was 
purified by flash column chromatography (3.5-6.6 % 2 M NH3-methanol in dichloromethane) to 
afford the product 22 as a light tan amorphous solid (0.078 g, 38 % over 3 steps). IR (thin film): 
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νmax 2945, 1647, 1603, 1583, 1528, 1502, 1286, 1262 cm
-1. 1H NMR (500 MHz, DMSO-d6) δ 
10.07 (s, 2H), 8.56 (d, J = 2.0 Hz, 1H), 8.37 (d, J = 8.8 Hz, 1H), 8.22 (dd, J = 8.7, 2.0 Hz, 1H), 
7.88-7.84 (m, 2H), 7.58 (dd, J = 8.3, 2.2 Hz, 1H), 7.54 (d, J = 2.1 Hz, 1H), 7.51 (dd, J = 8.4, 2.2 
Hz, 1H), 7.24 (d, J = 8.5 Hz, 1H), 7.10 (d, J = 8.8 Hz, 1H), 6.98 (d, J = 8.4 Hz, 1H), 4.47 (t, J = 
6.7 Hz, 2H), 4.34 – 4.27 (m, 4H), 2.39 (t, J = 7.1 Hz, 2H), 2.24 (s, 3H), 2.17 (s, 6H), 1.93 (p, J = 
6.8 Hz, 2H). 13C NMR (126 MHz, DMSO-d6) δ 164.94, 164.35, 162.88, 147.63, 146.34, 142.93, 
140.17, 137.29, 136.33, 130.10, 130.01, 128.76, 128.39, 128.12, 127.69, 126.73, 123.98, 121.19, 
118.62, 118.11, 116.84, 116.66, 113.98, 64.38, 64.02, 55.76, 45.21, 26.55, 17.48. HRMS (ESI+): 
calcd for C31H33N4O5 (M + H)
+, 541.2446; found 541.24423. 
N-(5-(2,3-Dihydrobenzo[b][1,4]dioxine-6-carboxamido)-2-methylphenyl)-2-(3-
morpholinopropoxy)quinoline-6-carboxamide 23 
4-(3-Hydroxypropyl)morpholine (0.171 mL, 1.24 mmol), NaH (60 % mineral oil, 0.047 g, 
1.19 mmol) and 6-bromo-2-chloroquinoline (0.250 g, 1.03 mmol) in anhydrous THF (3.50 mL) 
were reacted according to method E. The reaction mixture was heated for 16 h. Purification 
using flash column chromatography (1.5-3.5 % methanol in dichloromethane) gave 4-(3-((6-
bromoquinolin-2-yl)oxy)propyl)morpholine (221 mg) as a white amorphous solid, which was 
used directly in the next step. 
n-BuLi (1.56 M in hexanes, 0.460 mL, 0.717 mmol) and 4-(3-((6-bromoquinolin-2-
yl)oxy)propyl)morpholine (0.210 g, 0.598 mmol) in anhydrous THF (2.00 mL) were reacted 
according to method F to afford 2-(3-morpholinopropoxy)quinoline-6-carboxylic acid (0.273 g) 
as a yellow amorphous solid, which was used in the next step without further purification. 
2-(3-Morpholinopropoxy)quinoline-6-carboxylic acid hydrochloride (0.076 g, 0.188 mmol), 
HATU (0.089 g, 0.234 mmol) and  N-(3-amino-4-methylphenyl)-2,3-
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dihydrobenzo[b][1,4]dioxine-6-carboxamide 18 (0.040 g, 0.141 mmol) in N,N-
diisopropylethylamine (0.139 mL, 0.797 mmol) and anhydrous DMF (1.35 mL) were reacted 
according to method B. The crude product was purified by flash column chromatography to 
afford compound 23 as a white amorphous solid (51.0 mg, 47 % over 3 steps). IR (film): νmax 
3189, 2934, 1636, 1504, 1293, 1066, 819 cm-1. 1H NMR (500 MHz, DMSO-d6) δ 10.07 (s, 2H), 
8.56 (d, J = 2.1 Hz, 1H), 8.37 (d, J = 8.9 Hz, 1H), 8.22 (dd, J = 8.7, 2.0 Hz, 1H), 7.88 – 7.83 (m, 
2H), 7.58 (dd, J = 8.4, 2.2 Hz, 1H), 7.54 (d, J = 2.2 Hz, 1H), 7.51 (dd, J = 8.5, 2.2 Hz, 1H), 7.24 
(d, J = 8.3 Hz, 1H), 7.10 (d, J = 8.8 Hz, 1H), 6.98 (d, J = 8.4 Hz, 1H), 4.49 (t, J = 6.6 Hz, 2H), 
4.34 – 4.27 (m, 4H), 3.59 (t, J = 4.7 Hz, 4H), 2.50-2.44 (m, 2H), 2.39 (br s, 4H), 2.24 (s, 3H), 
1.97 (p, J = 6.7 Hz, 2H). 13C NMR (126 MHz, DMSO-d6) δ 164.95, 164.36, 162.88, 147.62, 
146.35, 142.94, 140.21, 137.30, 136.34, 130.12, 130.03, 128.77, 128.42, 128.14, 127.70, 126.72, 
124.00, 121.21, 118.63, 118.12, 116.85, 116.67, 114.00, 66.20, 64.40, 64.33, 64.03, 54.93, 53.34, 
25.47, 17.49. (2 carbons missing) HRMS (ESI+): calcd for C33H35N4O6 (M + H)
+, 583.2551; 
found 583.2586. 
N-(5-(2,3-Dihydrobenzo[b][1,4]dioxine-6-carboxamido)-2-methylphenyl)-2-(3-(piperidin-1-
yl)propoxy)quinoline-6-carboxamide 24 
1-Piperidinepropanol (0.235 mL, 1.55 mmol), NaH (60 % in mineral oil, 0.059 g) and 6-
bromo-2-chloroquinoline (0.300 g, 1.24 mmol) in anhydrous THF (4.00 mL) were reacted 
according to method E. The reaction was heated for 5 h. Purification using flash column 
chromatography (2.5-6 % methanol in dichloromethane) isolated 6-bromo-2-(3-(piperidin-1-
yl)propoxy)quinoline (329 mg) as a yellow oil, which was used directly in the next step. 
n-BuLi (1.56 M in hexanes, 0.732 mL, 1.14 mmol) and 6-bromo-2-(3-(piperidin-1-
yl)propoxy)quinoline (0.319 g, 0.913 mmol) in anhydrous THF (3.10 mL) were reacted 
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according to method F to afford the crude product, which was used in the next step without 
further purification. 
2-(3-(Piperidin-1-yl)propoxy)quinoline-6-carboxylic acid hydrochloride (76 mg, 0.188 mmol), 
HATU (89 mg, 0.234 mmol), and  N-(3-amino-4-methylphenyl)-2,3-
dihydrobenzo[b][1,4]dioxine-6-carboxamide 18 (40 mg, 0.141 mmol) in N,N-
diisopropylethylamine (0.139 mL, 0.797 mmol) and anhydrous DMF (1.35 mL) were reacted 
according to method B. The crude product was purified by flash column chromatography (3.5-15 
% methanol in dichloromethane) to afford compound 24 as a white amorphous solid (53 mg, 49 
% over 3 steps). IR (film): νmax 3257, 2928, 1601, 1526, 1284, 1064, 818 cm
-1. 1H NMR (500 
MHz, DMSO-d6) δ 10.07 (s, 2H), 8.57 (d, J = 2.1 Hz, 1H), 8.38 (d, J = 8.9 Hz, 1H), 8.23 (dd, J 
= 8.8, 2.1 Hz, 1H), 7.89 – 7.83 (m, 2H), 7.58 (dd, J = 8.3, 2.1 Hz, 1H), 7.54 (d, J = 2.1 Hz, 1H), 
7.51 (dd, J = 8.5, 2.2 Hz, 1H), 7.24 (d, J = 8.4 Hz, 1H), 7.10 (d, J = 8.8 Hz, 1H), 6.98 (d, J = 8.4 
Hz, 1H), 4.49 (t, J = 6.5 Hz, 2H), 4.34 – 4.26 (m, 4H), 2.70-2.30 (m, 6H), 2.24 (s, 3H), 2.02 (br 
s, 2H), 1.56 (br s, 4H), 1.42 (br s, 2H). 13C NMR (126 MHz, DMSO-d6) δ 164.94, 164.37, 
162.80, 147.59, 146.35, 142.94, 140.25, 137.31, 136.33, 130.12, 130.06, 128.78, 128.44, 128.15, 
127.69, 126.72, 124.03, 121.20, 118.64, 118.14, 116.85, 116.67, 113.96, 64.40, 64.21, 64.03, 
54.82, 53.67, 24.99, 23.34, 17.48, (3 carbons missing). HRMS (ESI+): calcd for C34H37N4O5 (M 
+ H)+, 581.2758; found 581.2759. 
N-(5-(2,3-Dihydrobenzo[b][1,4]dioxine-6-carboxamido)-2-methylphenyl)-2-(2-(piperidin-1-
yl)ethoxy)quinoline-6-carboxamide 25 
4-(2-Hydroxyethyl)piperidine (0.197 mL, 1.49 mmol), NaH (60 % in mineral oil, 0.057 g, 1.42 
mmol) and 6-bromo-2-chloroquinoline (0.300 g, 1.24 mmol) in anhydrous THF (4 mL) were 
reacted according to method E. The reaction mixture was heated for 5 h. Purification by flash 
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column chromatography (4-5 % methanol in dichloromethane) isolated 334 mg of a pale yellow 
oil, which was used directly in the next step. 
n-BuLi (2.28 M in hexanes, 0.437 mL, 0.996 mmol) and 6-bromo-2-(2-(piperidin-1-
yl)ethoxy)quinoline (0.204 g, 0.664 mmol) in anhydrous THF (2.20 mL) were reacted according 
to method F (a precipitate formed after addition of n-BuLi therefore further THF (1.0 mL) was 
added to facilitate stirring) to afford the crude product, which was used in the next step without 
further purification. 
2-(2-(Piperidin-1-yl)ethoxy)quinoline-6-carboxylic acid hydrochloride (85 %, 93 mg, 0.234 
mmol), HATU (111 mg, 0.293 mmol), and N-(3-amino-4-methylphenyl)-2,3-
dihydrobenzo[b][1,4]dioxine-6-carboxamide 18 (50 mg, 0.176 mmol)  in N,N-
diisopropylethylamine (0.174 mL, 0.997 mmol) and anhydrous DMF (1.5 mL) were reacted 
according to method B. The crude product was purified by flash column chromatography (3.5-10 
% methanol in dichloromethane) to afford compound 25 as a white amorphous solid (75 mg, 75 
%). IR (film): νmax 3230, 2932, 1636, 1504, 1291, 1040, 822 cm
-1. 1H NMR (500 MHz, DMSO-
d6) δ 10.07 (s, 2H), 8.57 (d, J = 1.9 Hz, 1H), 8.38 (d, J = 8.9 Hz, 1H), 8.22 (dd, J = 8.7, 2.0 Hz, 
1H), 7.88 – 7.84 (m, 2H), 7.58 (dd, J = 8.3, 2.2 Hz, 1H), 7.54 (d, J = 2.1 Hz, 1H), 7.51 (dd, J = 
8.4, 2.2 Hz, 1H), 7.24 (d, J = 8.5 Hz, 1H), 7.11 (d, J = 8.8 Hz, 1H), 6.98 (d, J = 8.4 Hz, 1H), 
4.60 – 4.54 (m, 2H), 4.34 – 4.27 (m, 4H), 2.75 (br s, 2H), 2.61 – 2.36 (br s, 4H), 2.24 (s, 3H), 
1.51 (br s, 4H), 1.39 (br s, 2H). 13C NMR (126 MHz, DMSO-d6) δ 165.39, 164.81, 163.15, 
148.00, 146.80, 143.39, 140.71, 137.75, 136.79, 130.57, 130.52, 129.23, 128.88, 128.57, 128.15, 
127.21, 124.48, 121.65, 119.08, 118.58, 117.30, 117.12, 114.47, 64.86, 64.48, 63.73, 57.50, 
54.76, 25.95, 24.30, 17.94 (2 carbons missing). HRMS (ESI+): calcd for C33H35N4O5 (M + H)
+, 
567.2602; found 567.2598. 
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N-(5-(2,3-Dihydrobenzo[b][1,4]dioxine-6-carboxamido)-2-methylphenyl)-2-(2-(pyrrolidin-1-
yl)ethoxy)quinoline-6-carboxamide 26 
NaH (60 % in mineral oil, 57 mg, 1.42 mmol), 4(2-hydroxyethyl)pyrrolidine (171 mg, 1.48 
mmol) and bromo-2-chloroquinoline (300 mg, 1.24 mmol) were reacted according to method E. 
The reaction was heated for 4 h. Purification by flash column chromatography using a gradient 
of 2 to 5 % methanol in dichloromethane afforded a pale yellow oil (329 mg), which was used 
directly in the next step.  
n-BuLi (1.62 M in hexanes, 0.76 mL, 1.23 mmol) and 6-bromo-2-(2-(pyrrolidin-1-
yl)ethoxy)quinolone (38 mg, 0.990 mmol) in anhydrous THF (3.3 mL) were reacted according to 
method F to afford the crude product, which was used in the next step without further 
purification. 
2-(2-(Pyrrolidin-1-yl)ethoxy)quinoline-6-carboxylic acid hydrochloride (89 mg, 0.23 mmol), 
HATU (111 mg, 0.29 mmol) and N-(3-amino-4-methylphenyl)-2,3-dihydrobenzo[b][1,4]dioxine-
6-carboxamide (50 mg, 0.18 mmol) in N,N-diisopropylethylamine (0.17 mL, 1.0 mmol) and 
anhydrous DMF (1.5 mL) was reacted according to method B. The crude product was purified 
by flash column chromatography using a gradient of 5-12 % methanol in dichloromethane to 
afford the product 26 as a white amorphous solid (66 mg, 70 %). IR (solid): νmax 1637, 1601, 
1581, 1289, 1065, 819 cm-1. 1H NMR (500 MHz, DMSO-d6) δ 10.07 (s, 2H), 8.57 (d, J = 2.0 
Hz, 1H), 8.38 (d, J = 8.8 Hz, 1H), 8.22 (dd, J = 8.7, 2.0 Hz, 1H), 7.88 – 7.84 (m, 2H), 7.58 (dd, 
J = 8.3, 2.2 Hz, 1H), 7.54 (d, J = 2.1 Hz, 1H), 7.51 (dd, J = 8.5, 2.2 Hz, 1H), 7.24 (d, J = 8.5 
Hz, 1H), 7.12 (d, J = 8.8 Hz, 1H), 6.98 (d, J = 8.4 Hz, 1H), 4.57 (t, J = 5.8 Hz, 2H), 4.34 – 4.27 
(m, 4H), 2.89 (br s, 2H), 2.58 (br s, 4H), 2.23 (s, 3H), 1.70 (br s, 4H). 13C NMR (126 MHz, 
DMSO-d6) δ 165.39, 164.81, 163.15, 148.00, 146.80, 143.39, 140.72, 137.76, 136.79, 130.57, 
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130.52, 129.23, 128.88, 128.58, 128.15, 127.21, 124.49, 121.65, 119.08, 118.58, 117.30, 117.12, 
114.48, 65.03, 64.86, 64.48, 54.58, 54.42, 40.32, 40.15, 23.61, 17.95. HRMS (ESI+): calcd for 
C32H33N4O5 (M + H)
+, 553.2446; found 553.2467. 
Preparation of compounds in Figure 4: 
N-(4-Methyl-3-(6-(2-propionamidoethoxy)-2-naphthamido)phenyl)-2,3-
dihydrobenzo[b][1,4]dioxine-6-carboxamide 27  
Propionyl chloride (2.5 µL, 0.029 mmol) was added to a solution of 2-(2-aminoethoxy)-N-(5-
(2,3-dihydrobenzo[b][1,4]dioxine-6-carboxamido)-2-methylphenyl)quinoline-6-carboxamide 29 
(0.013 g, 0.026 mmol) in anhydrous dichloromethane (0.75 mL) and DMF (0.15 mL). The 
reaction mixture was stirred at room temperature for 2.5 h, concentrated to remove 
dichloromethane, then diluted with water, extracted with dichloromethane (3x), dried over 
magnesium sulfate, filtered and concentrated. Heptane was added and concentrated (2x) to 
remove residual DMF. The crude material was purified by flash column chromatography using a 
gradient of 2-3.5 % methanol in dichloromethane to afford the title compound 27 (10 mg, 71 %) 
as a white amorphous solid. IR (thin film): νmax 2934, 1645, 1529, 1502, 1286, 1262, 1065 cm
-1. 
1H NMR (500 MHz, DMSO-d6) δ 10.08 (s, 1H), 10.07 (s, 1H), 8.57 (d, J = 2.0 Hz, 1H), 8.39 (d, 
J = 8.8 Hz, 1H), 8.23 (dd, J = 8.7, 2.1 Hz, 1H), 8.04 (br t, J = 5.5 Hz, 1H), 7.88 – 7.84 (m, 2H), 
7.58 (dd, J = 8.4, 2.2 Hz, 1H), 7.54 (d, J = 2.1 Hz, 1H), 7.51 (dd, J = 8.5, 2.2 Hz, 1H), 7.24 (d, J 
= 8.4 Hz, 1H), 7.11 (d, J = 8.8 Hz, 1H), 6.98 (d, J = 8.4 Hz, 1H), 4.47 (t, J = 5.7 Hz, 2H), 4.34 – 
4.27 (m, 4H), 3.51 (q, J = 5.7 Hz, 2H), 2.24 (s, 3H), 2.10 (q, J = 7.6 Hz, 2H), 0.99 (t, J = 7.6 Hz, 
3H). 13C NMR (126 MHz, DMSO-d6) δ 173.66, 165.39, 164.81, 163.13, 147.95, 146.80, 143.39, 
140.76, 137.75, 136.79, 130.58, 129.23, 128.91, 128.59, 128.15, 127.21, 124.54, 121.66, 119.08, 
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118.59, 117.30, 117.12, 114.42, 65.03, 64.86, 64.49, 38.44, 28.86, 17.95, 10.36, (1 carbon 
missing). HRMS (ESI+): calcd for C31H31N4O6 (M + H)
+, 555.2238; found 555.2228.  
N-(5-(2,3-Dihydrobenzo[b][1,4]dioxine-5-carboxamido)-2-methylphenyl)-2-(2-(pyrrolidin-1-
yl)ethoxy)quinoline-6-carboxamide 28  
2,3-Dihydrobenzo[b][1,4]dioxine-5-carboxylic acid (980 mg, 5.44 mmol), oxalyl chloride 
(0.552 mL, 6.53 mmol) and DMF (0.011 mL, 0.14 mmol) in anhydrous dichloromethane (14 
mL) were reacted according to method A. The resulting acid chloride was dissolved in 
anhydrous dichloromethane (9 mL) and added dropwise to a solution of 4-methyl-3-nitroaniline 
2 (828 mg, 5.44 mmol) and pyridine (0.88 mL, 10.88 mmol) in anhydrous dichloromethane (15 
mL). A precipitate formed during the addition. The reaction mixture was stirred at room 
temperature overnight, and then concentrated. The resulting amorphous solid was suspended in 
methanol, diluted with water and then isolated by filtration and washed with water to afford the 
title compound as a pale brown amorphous solid (1.57 g, 92 %). 1H NMR (500 MHz, DMSO-d6) 
δ 10.45 (s, 1H), 8.53 (d, J = 2.2 Hz, 1H), 7.88 (dd, J = 8.3, 2.2 Hz, 1H), 7.49 (d, J = 8.5 Hz, 
1H), 7.16 (dd, J = 7.6, 1.6 Hz, 1H), 7.04 (dd, J = 8.1, 1.6 Hz, 1H), 6.97 – 6.92 (m, 1H), 4.39 – 
4.36 (m, 2H), 4.34 – 4.30 (m, 2H), 2.50 (s, 3H). 13C NMR (126 MHz, DMSO-d6) δ 164.91, 
149.06, 144.14, 141.73, 138.33, 133.53, 127.95, 125.57, 124.69, 121.71, 121.25, 119.85, 115.23, 
64.96, 64.23, 19.68. HRMS (ESI+): calcd for C16H15N2O5 (M + H)
+, 315.0975; found 315.0976.  
Palladium (10 % on activated carbon, 0.325 g) and N-(4-methyl-3-nitrophenyl)-2,3-
dihydrobenzo[b][1,4]dioxine-5-carboxamide (1.50 g, 4.77 mmol) in ethanol (32 mL) and ethyl 
acetate (32 mL) were reacted according to method D to afford N-(3-amino-4-methylphenyl)-2,3-
dihydrobenzo[b][1,4]dioxine-5-carboxamide (1.30 g, 96 %) as a white amorphous solid. 1H 
NMR (500 MHz, CDCl3) δ 9.35 (s, 1H), 7.80 (dd, J = 7.8, 1.6 Hz, 1H), 7.34 (br s, 1H), 7.03 (dd, 
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J = 8.0, 1.7 Hz, 1H), 7.01 – 6.92 (m, 2H), 6.76 (dd, J = 8.0, 2.0 Hz, 1H), 4.49 – 4.44 (m, 3H), 
4.36 – 4.30 (m, 3H), 3.54 (br s, 2H). 13C NMR (126 MHz, CDCl3) δ 162.58, 145.09, 143.61, 
141.73, 137.17, 130.51, 124.23, 122.59, 121.51, 121.00, 118.39, 110.47, 107.22, 65.13, 63.59, 
16.91. HRMS (ESI+): calcd for C16H17N2O3 (M + H)
+, 286.1265; found 286.1263. RMS (ESI+): 
calcd for C16H17N2NaO3 (M + Na)
+, 307.1053; found 307.1048.  
2-(2-(Pyrrolidin-1-yl)ethoxy)quinoline-6-carboxylic acid hydrochloride (95 mg, 0.253 mmol), 
HATU, (104 mg, 0.274 mmol), and  N-(3-amino-4-methylphenyl)-2,3-
dihydrobenzo[b][1,4]dioxine-5-carboxamide (0.060 g, 0.211 mmol) in N,N-
diisopropylethylamine (0.147 mL, 0.844 mmol) and anhydrous DMF (2 mL) were reacted 
according to method B. The crude product was purified by flash column chromatography using a 
gradient of 5-10 % methanol in dichloromethane to afford the title compound 28 as a cream 
amorphous solid (61 mg, 52 %). IR (thin film): νmax 2926, 1651, 1619, 1601, 1527, 1470, 1282 
cm-1. 1H NMR (500 MHz, DMSO-d6) δ 10.10 (s, 1H), 10.09 (s, 1H), 8.57 (d, J = 2.0 Hz, 1H), 
8.38 (d, J = 8.8 Hz, 1H), 8.23 (dd, J = 8.7, 2.0 Hz, 1H), 7.86 (d, J = 8.7 Hz, 1H), 7.81 (d, J = 2.1 
Hz, 1H), 7.53 (dd, J = 8.3, 2.1 Hz, 1H), 7.24 (d, J = 8.4 Hz, 1H), 7.15 (dd, J = 7.6, 1.6 Hz, 1H), 
7.12 (d, J = 8.8 Hz, 1H), 7.01 (dd, J = 8.0, 1.7 Hz, 1H), 6.92 (t, J = 7.8 Hz, 1H), 4.57 (t, J = 5.8 
Hz, 2H), 4.40 – 4.35 (m, 2H), 4.30 (dt, J = 3.8, 2.3 Hz, 2H), 2.91 (br s, 2H), 2.60 (br s, 4H), 2.23 
(s, 3H), 1.71 (s, 4H). 13C NMR (126 MHz, DMSO-d6) δ 165.38, 164.26, 163.15, 148.01, 144.11, 
141.65, 140.73, 137.51, 136.95, 130.72, 130.45, 129.44, 128.90, 128.62, 127.20, 126.15, 124.49, 
121.72, 121.17, 119.50, 118.45, 117.95, 114.48, 64.93, 64.21, 54.55, 54.42, 23.60, 17.98, (2 
carbons missing). HRMS (ESI+): calcd for C32H33N4O5 (M + H)
+, 553.2445; found 553.2424.  
2-(2-Aminoethoxy)-N-(5-(2,3-dihydrobenzo[b][1,4]dioxine-6-carboxamido)-2-
methylphenyl)quinoline-6-carboxamide 29  
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NaH (60 % in mineral oil, 0.112 g, 2.79 mmol), tert-butyl N-(2-hydroxyethyl)carbamate (0.43 
mL, 2.79 mmol) and 6-bromo-2-chloroquinoline (0.564 g, 2.33 mmol) in anhydrous THF (13 
mL) were reacted according to method E. The reaction was heated for 5 h. Purification by flash 
column chromatography using a gradient of 20-25 % diethyl ether in petroleum ether afforded 
tert-butyl (2-((6-bromoquinolin-2-yl)oxy)ethyl)carbamate as a white amorphous solid (248 mg, 
29 %). 1H NMR (500 MHz, CDCl3) δ 7.92 (d, J = 8.9 Hz, 1H), 7.88 (d, J = 1.6 Hz, 1H), 7.74 – 
7.66 (m, 2H), 6.94 (d, J = 8.8 Hz, 1H), 5.14 (br s, 1H), 4.56 (t, J = 5.1 Hz, 2H), 3.61 (br s, 2H), 
1.46 (s, 9H). 13C NMR (126 MHz, CDCl3) δ 145.03, 137.93, 132.86, 129.48, 128.93, 117.42, 
113.99, 65.52, 40.14, 28.40, (2 carbons missing). HRMS (ESI+): calcd for C16H20
79BrN2O3 (M + 
H)+, 367.0652; found 367.0649.  
n-BuLi (2.12 M in hexanes, 0.350 mL, 0.743 mmol) and tert-butyl (2-((6-bromoquinolin-2-
yl)oxy)ethyl)carbamate (0.124 g, 0.338 mmol) in anhydrous THF (3.0 mL) were reacted 
according to method F. The reaction was quenched with water and the reaction mixture 
concentrated to remove THF. The resulting aqueous solution was washed with ethyl acetate (1x) 
(brine was added to help clear the emulsion formed) and then acidified with 2 M HCl to pH 2-3. 
The aqueous layer was extracted with dichloromethane (3x) and the combined organic layer 
dried over magnesium sulfate to afford 2-(2-((tert-butoxycarbonyl)amino)ethoxy)quinoline-6-
carboxylic acid as a white amorphous solid (52 mg, 46 %). 1H NMR (500 MHz, DMSO-d6) δ 
13.06 (br s, 1H), 8.56 (d, J = 1.9 Hz, 1H), 8.41 (d, J = 8.9 Hz, 1H), 8.13 (dd, J = 8.7, 2.0 Hz, 
1H), 7.80 (d, J = 8.8 Hz, 1H), 7.07 (d, J = 8.9 Hz, 1H), 7.04 (t, J = 5.7 Hz, 1H), 4.43 (t, J = 5.8 
Hz, 2H), 3.37 (q, J = 5.6 Hz, 2H), 1.37 (s, 9H). HRMS (ESI+): calcd for C17H21N2O5 (M + H)
+, 
333.1445; found 333.1447.  
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2-(2-((tert-Butoxycarbonyl)amino)ethoxy)quinoline-6-carboxylic acid (46 mg, 0.138 mmol), 
HATU (66 mg, 0.173 mmol) and  N-(3-aminophenyl)-2,3-dihydrobenzo[b][1,4]dioxine-6-
carboxamide (39 mg, 0.138 mmol) in N,N-diisopropylethylamine (0.073 mL, 0.415 mmol) and 
anhydrous DMF (2 mL) were reacted according to method B. The crude material was purified by 
flash column chromatography using a gradient of 1-3 % methanol in dichloromethane to afford 
the product as an off-white amorphous solid (77 mg, 56 %). 1H NMR (500 MHz, DMSO-d6) δ 
10.07 (s, 1H), 10.07 (s, 1H), 8.57 (d, J = 2.1 Hz, 1H), 8.39 (d, J = 8.8 Hz, 1H), 8.22 (dd, J = 8.8, 
2.1 Hz, 1H), 7.86 (d, J = 8.8 Hz, 1H), 7.86 (d, J = 2.2 Hz, 1H), 7.58 (dd, J = 8.5, 2.2 Hz, 1H), 
7.54 (d, J = 2.0 Hz, 1H), 7.51 (dd, J = 8.4, 2.2 Hz, 1H), 7.24 (d, J = 8.5 Hz, 1H), 7.09 (d, J = 8.9 
Hz, 1H), 7.06 (t, J = 5.6 Hz, 1H), 6.98 (d, J = 8.4 Hz, 1H), 4.45 (t, J = 5.7 Hz, 2H), 4.33 – 4.28 
(m, 2H), 3.39 (ap q, J = 5.7 Hz, 2H), 2.24 (s, 3H), 1.38 (s, 9H). 13C NMR (126 MHz, DMSO-d6) 
δ 165.39, 164.81, 163.12, 147.95, 146.80, 143.39, 140.71, 137.76, 136.79, 130.57, 129.23, 
128.88, 128.58, 128.15, 127.21, 124.53, 121.66, 119.08, 118.58, 117.30, 117.12, 114.47, 78.21, 
65.13, 64.86, 64.48, 39.72, 28.70, 17.95, (2 carbons missing). HRMS (ESI+): calcd for 
C33H35N4O7 (M + H)
+, 599.2500; found 599.2495. 
Trifluoroacetic acid (0.75 mL) was added to a solution of tert-butyl (2-((6-((5-(2,3-
dihydrobenzo[b][1,4]dioxine-6-carboxamido)-2-methylphenyl)carbamoyl)quinolin-2-
yl)oxy)ethyl)carbamate (0.039 g, 0.065 mmol) in anhydrous dichloromethane (0.75 mL) and the 
reaction mixture was stirred at room temperature for 75 min, concentrated, added 
dichloromethane and concentrated again. Diluted with a small amount of methanol, then a 1:1 
mixture of sat. NaHCO3 (aq.) was slowly added. The resulting precipitate was isolated by 
filtration and washed with water. The crude material was purified by flash column 
chromatography using 10 % methanol in dichloromethane then a gradient of 5 to 9 % 2 M NH3 
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methanol/DCM to afford the title compound (22 mg, 68 %) as an off-white amorphous solid. 1H 
NMR (500 MHz, DMSO-d6) δ 10.08 (s, 2H), 8.57 (d, J = 2.0 Hz, 1H), 8.39 (d, J = 8.9 Hz, 1H), 
8.22 (dd, J = 8.7, 2.1 Hz, 1H), 7.89 – 7.84 (m, 2H), 7.58 (dd, J = 8.3, 2.2 Hz, 1H), 7.54 (d, J = 
2.1 Hz, 1H), 7.51 (dd, J = 8.5, 2.2 Hz, 1H), 7.24 (d, J = 8.4 Hz, 1H), 7.12 (d, J = 8.7 Hz, 1H), 
6.99 (d, J = 8.4 Hz, 1H), 4.42 (t, J = 5.8 Hz, 2H), 4.33 – 4.28 (m, 4H), 2.99 (t, J = 5.9 Hz, 2H), 
2.25 (s, 3H), 2.06 (br s, 2H). 13C NMR (126 MHz, DMSO-d6) δ 165.41, 164.81, 163.40, 148.07, 
146.81, 143.39, 140.64, 137.76, 136.80, 130.58, 130.48, 129.23, 128.86, 128.58, 128.15, 127.20, 
124.48, 121.66, 119.08, 118.58, 117.31, 117.12, 114.51, 68.85, 64.86, 64.49, 41.13, 17.96. 
HRMS (ESI+): calcd for C28H27N4O5 (M + H)
+, 499.1976; found 499.1974. 
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Atomic coordinates and structure factors for the crystal structures of pirin with compound 26 
can be accessed using PDB code:  5JCT. Authors will release the atomic coordinates and 
experimental data upon article publication. 
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CTB, Cell Titer Blue; ELISA, enzyme-linked immunosorbent assay; HSF1, heat-shock factor 
protein 1; HSP70, 70 kilodalton heat-shock proteins; SAR, structure activity relationship; 
HSP72, heat-shock 70 KDa protein 1; HSP90, heat-shock protein 90; 17-AAG, Tanespimycin 
(17-N-allylamino-17-demethoxygeldanamycin); ELISA, enzyme-linked immunosorbent assay; 
BRAF, B-Raf proto-oncogene, serine/threonine kinase; KIT, tyrosine protein kinase KIT; 
PDGFRA, platelet-derived growth factor receptor alpha polypeptide; PDGFRB, beta-type 
platelet-derived growth factor receptor; HTS, high-throughput screen; nM, nanomolar; µM, 
micromolar; IC50, half minimal (50%) inhibitory concentration; GI50, concentration for 50% of 
maximal inhibition of cell proliferation; CDK2, Cyclin-dependent kinase 2; CDK9, Cyclin-
dependent kinase 9; SEM, standard error of the mean; K,; dissociation constant; HATU, 1-
[bis(dimethylamino)methylene]-1H-1,2,3-triazolo[4,5-b]pyridinium 3-oxid hexafluorophosphate; 
MLM, mouse liver microsomes; KS, kinetic solubility; HBF, hepatic blood flow; EMT, 
Epithelial-mesenchymal transition; SPR, surface plasmon resonance; GPCR, G protein-coupled 
receptors, NFκB, nuclear factor kappa-light-chain-enhancer of activated B cells; EAF2/U19, 
ELL-associated factor 2; NRF2, nuclear factor erythroid 2 related factor 2; BCL3, B-cell 
lymphoma 3-encoded protein; NFI/CTF1, Nuclear factor I; p65, nuclear factor NF-kappa-B p65 
subunit; EMT, Epithelial–mesenchymal transition; GSK3β, Glycogen synthase kinase 3 beta; 
PDE6D, Retinal rod rhodopsin-sensitive cGMP 3',5'-cyclic phosphodiesterase subunit delta; 
SILAC, Stable isotope labeling by amino acids in cell culture; PK, pharmacokinetics; AUC, area 
under the curve; AUCu, unbound area under the curve; Cav
0-24hrs, average concentration over a 24 
hr period; po, per os, oral dose; qd, quaque die, once-a-day dose; Cl, clearance; Clu, unbound 
clearance; Vss, volume of distribution at steady-state; Vdu, unbound volume of distribution; %F, 
percentage oral bioavailability; fup, fraction unbound in plasma; fub, fraction unbound in blood; 
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fua, fraction unbound in the assay; B:P, blood to plasma ratio; CYP450, cytochrome P450; DMF, 
dimethylformamide; DCM, dichloromethane; DIPEA, diisopropylethylamine; THF 
tetrahydrofuran. 
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heat-shock factor 1 (HSF1) are associated with poor prognosis in breast cancer. Proc. Natl. Acad. 
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Sci. U.S.A. 2011, 108, 18378-18383. (b) Fang, F.; Chang, R.; Yang, L. Heat shock factor 1 
promotes invasion and metastasis of hepatocellular carcinoma in vitro and in vivo. Cancer 2012, 
118, 1782-1794. (c) Scott, K. L.; Nogueira, C.; Heffernan, T. P.; Doorn, R. V.; Dhakal, S.; 
Hanna, J. A.; Min, C.; Jaskelioff, M.; Xiao, Y.; Wu, C-J; Cameron, L. A.; Perry, S. R.; Zeid, R.; 
Tamar Feinberg, T.; Kim, M.; Woude, G. V.; Granter, S. R.; Bosenberg, M.; Chu, G. C.; 
DePinho, R. A.; Rimm, D. L.; Chin, L. Pro-invasion metastasis drivers in early stage melanoma 
are oncogenes. Cancer Cell 2011, 20, 92-103. 
(17) For a discussion of transcription inhibitors in oncology see: (a) Bensaude, O. Inhibiting 
eukaryotic transcription, which compound to choose? how to evaluate its activity? Transcr. 
2011, 2, 103-108. (b) Stellrecht, C. M.; Chen, L. S. Transcription inhibition as a therapeutic 
target for cancer. Cancers 2011, 3, 4170-4190. (c) Kwiatkowski, N.; Zhang, T.; Rahl, P. B.; 
Abraham, B. J.; Reddy, J.; Ficarro, S. B.; Dastur, A.; Amzallag, A.; Ramaswamy, S.; Tesar, B.; 
Jenkins, C. E.; Hannett, N. M.; McMillin, D.; Sanda, T.; Sim, T.; Kim, N. D.; Look, T.; 
Mitsiades, C. S.; Weng, A. P.; Brown, J. R.; Benes, C. H.; Marto, J. A.; Young, R. A.; Gray, N. 
S. Targeting transcription regulation in cancer with a covalent CDK7 inhibitor. Nature 2014, 
511, 616-620. (d) Nguyen, T. K.; Grant, S. Dinaciclib (SCH727965) inhibits the unfolded protein 
response through a CDK1- and 5-dependent mechanism. Mol. Cancer Ther. 2013, 20, 662-674. 
(e) Lam, F.; Abbas, A. Y.; Shao, H.; Teo, T.; Adams, J.; Peng Li, P.; Bradshaw, T. D.; Fischer, 
P. M.; Walsby, E.; Pepper, C.; Chen, Y.; Ding, J.; Wang, S. Targeting RNA transcription and 
translation in ovarian cancer cells with pharmacological inhibitor CDKI-73. Oncotarget 2014, 5, 
7691-7704. (f) Wang, S.; Griffiths, G.; Midgley, C. A.; Barnett, A. L.; Cooper, M.; Grabarek, J.; 
Ingram, L.; Jackson, W.; Kontopidis, G.; McClue, S. J.; McInnes, C.; McLachlan, J.; Meades, 
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C.; Mezna, M.; Stuart, I.; Thomas, M. P.; Zheleva, D. I.; Lane, D. P.; Jackson, R. C.; Glover, D. 
M.; Blake D. G.; Fischer, P. M. Discovery and characterization of 2-anilino-4-(thiazol-5-
yl)pyrimidine transcriptional CDK inhibitors as anticancer agents. Chem. Biol. 2010, 17, 1111-
1121. (g) Villicana, C.; Cruz, G.; Zurita, M. The basal transcription machinery as a target for 
cancer therapy. Cancer Cell Int. 2014, 14, 18. 
(18) Solimini, N. L.; Luo, J.; Elledge, S. J. Non-oncogene addiction and the stress phenotype 
of cancer cells. Cell 2007, 130, 986-988. 
(19) (a) Zou, J.; Guo, Y.; Guettouche, T.; David F. Smith, D. F.; Voellmy, R. Repression of 
heat shock transcription factor HSF1 activation by HSP90 (HSP90 complex) that forms a stress-
sensitive complex with HSF1. Cell 1998, 94, 471-480. (b) Doubrovin, M.; Che, J. T.; Serganova, 
I.; Moroz, E.; Solit, D. B.; Ageyeva, L.; Kochetkova, T.; Pillarsetti, N.; Finn, R.; Rosen, N.; 
Blasberg, R. G. Monitoring the induction of heat shock factor 1/heat shock protein 70 expression 
following 17-allylamino- demethoxygeldanamycin treatment by positron emission tomography 
and optical reporter gene imaging. Mol. Imaging 2012, 11, 67-76. (c) Au, Q.; Zhang, Y.; Barber, 
J. R.; Chung NG, S.; Zhang, B. Identification of inhibitors of HSF1 functional activity by high-
content target-based screening. J. Biomol. Screening 2009, 14, 1165-1175. 
(20) West, J. D.; Wang, Y.; Morano, K. A. Small molecule activators of the heat shock 
response: chemical properties, molecular targets, and therapeutic promise. Chem. Res. Toxicol. 
2012, 25, 2036-2053. 
(21) (a) Rocaglamide A: Santagata, S.; Mendillo, M. L; Tang, Y.; Subramanian, A.; Perley, C. 
C.; Roche, S. P.; Wong, B.; Narayan, R.; Kwon. H.; Koeva, M.; Amon, A.; Golub, T. R.; Porco 
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Jr., J. A.; Whitesell, L.; Lindquist, S. Tight coordination of protein translation and HSF1 
activation supports the anabolic malignant state. Science 2013, 341, 1238303. (b) Triptolide: 
Westerheide, S. D.; Kawahara. T. L. A.; Orton, K.; Morimoto, R. I. Triptolide, an inhibitor of the 
human heat shock response that enhances stress-induced cell death. J. Biol. Chem. 2006, 281, 
9616-9622. (c) BEZ235 and SNS-032: Acquaviva, J.; He, S.; Sang, J.; Smith, D. L.; Sequeira, 
M.; Zhang, C.; Bates, R. C.; Proia, D. A. mTOR inhibition potentiates HSP90 inhibitor activity 
via cessation of HSP synthesis. Mol. Cancer Res. 2014, 12, 703-713. (d) For Dinaciclib and 
SNS-032 see reference 28. 
(22) The compound library was provided by AstraZeneca, see reference 28. 
(23) 17-AAG was purchased from http://www.invivogen.com/17-aag (August 31, 2016). For a 
description of 17-AAG as an HSP90 inhibitor see: Powers, M. V.; Valenti, M.; Miranda, S.; 
Maloney, A.; Eccles, S. A.; Thomas, G.; Clarke, P. A.; Workman, P. Mode of cell death induced 
by the HSP90 inhibitor 17-AAG (tanespimycin) is dependent on the expression of pro-apoptotic 
BAX. Oncotarget 2013, 4, 1963-1965. 
(24) Jones, K.; Rye, C.; Chessum, N.; Cheeseman, M.; Pasqua, A. E.; Pike, K. G.; Faulder, P. 
F. Fused 1,4-dihydrodioxin derivatives as inhibitors of heat shock transcription factor 1. WO 
2015/049535 A1, April 9, 2015. 
(25) pIC50=-log10 IC50 (M). All results are quoted to 3 significant figures as geometric 
mean±standard error of the mean (SEM). The geometric mean and the number of repeats are 
quoted in the parenthesis. 
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(26) Hardcastle, A.; Boxall, K.; Richards, J.; Tomlin, P.; Sharp, S.; Clarke, P.; Workman, P.; 
Aherne, W. Solid-phase immunoassays in mechanism-based drug discovery: their application in 
the development of inhibitors of the molecular chaperone heat-shock protein 90. Assay Drug 
Dev. Technol. 2005, 3, 273-285. 
(27) Laitem, C.; Zaborowska, J.; Isa, N. F.; Kufs, J.; Dienstbier, M.; Murphy, S. CDK9 
inhibitors define elongation checkpoints at both ends of RNA polymerase II-transcribed genes. 
Nat. Struct. Mol. Biol. 2015, 22, 396-405. 
(28) Rye, C. S.; Chessum, N. E. A.; Lamont, S.; Pike, K. G.; Faulder, P.; Demeritt, J.; 
Kemmitt, P.; Tucker, J.; Zani, L.; Cheeseman, M. D.; Isaac, R.; Goodwin, L.; Boros, J.; 
Raynaud, F.; Hayes, A.; Henley, A.; de Billy, E.; Lynch, C. J.; Sharp, S. Y.; te Poele, R.; O’ Fee, 
L.; Foote, K. M.; Green, S.; Workman, P.; Jones, K. Discovery of 4,6-disubstituted pyrimidines 
as potent inhibitors of the heat shock factor (HSF1) stress pathway and CDK9. MedChemComm 
2016, 7, 1580-1586. 
(29) (a) Guettouche, T.; Boellmann, F.; Lane, W. S.; Voellmy, R. Analysis of phosphorylation 
of human heat shock factor 1 in cells experiencing a stress. BMC Biochem. 2005, 6:4. (b) 
Budzynski, M. A.; Puustinen, M. C.; Joutsen, J.; Sistonena, L. Uncoupling stress-inducible 
phosphorylation of heat shock factor 1 from its activation. Mol. Cell. Biol. 2015, 35, 2530-2540. 
(30) https://www.discoverx.com/services/drug-discovery-development-services/kinase-
profiling/kinomescan (August 31, 2016). 
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(31) http://www.thermofisher.com/uk/en/home/products-and-services/services/custom-
services/screening-and-profiling-services/selectscreen-profiling-service.html?icid=fr-dd-1 
(August 31, 2016). 
(32) All BRAF inhibitors were purchased from Selleckchem and were used without further 
purification, http://www.selleckchem.com (August 31, 2016). See supporting information for 
details. 
(33) All BRAF inhibitors were screened in the human ovarian carcinoma cell-line SK-OV-3. 
(34) Garnett, M. J.; Edelman, E. J.; Heidorn, S. J.; Greenman, C. D.; Dastur, A.; Lau, K. W.; 
Greninger, P.; Thompson, I. R.; Luo, X.; Soares, J.; Liu, Q.; Iorio, F.; Surdez, D.; Chen, L.; 
Milano, R. J.; Bignell, G. R.; Tam, A. T.; Davies, H.; Stevenson, J. A.; Barthorpe, S.; Lutz, S. R.; 
Kogera, F.; Lawrence, K.; Mclaren-Douglas, A.; Mitropoulos, X.; Mironenko, T.; Thi, H.; 
Richardson, L.; Zhou, W.; Jewitt, F.; Zhang, T.; O'Brien, P.; Boisvert, J. L.; Price, S.; Hur, W.; 
Yang, W.; Deng, X.; Butler, A.; Choi, H. G.; Chang, J.W.; Baselga, J.; Stamenkovic, I.; 
Engelman, J. A.; Sharma, S.V.; Delattre, O.; Saez-Rodriguez, J.; Gray, N. S.; Settleman, J.; 
Futreal, P. A.; Haber, D. A.; Stratton, M. R.; Ramaswamy, S.; Mcdermott, U.; Benes, C. H. 
Systematic identification of genomic markers of drug sensitivity in cancer cells. Nature 2012, 
483, 570-575. 
(35) ATCC: http://www.lgcstandards-atcc.org/products/all/HTB-77.aspx?geo_country=gb 
(August 31, 2016). For examples of using the SK-OV-3 cell-line in drug discovery see: (a) 
Huang, R. Y-J; Kuay, K. T.; Tan, T. Z.; Asad, M.; Tang, H. M.; Ng, A. H. C.; Ye, J.; Chung, V. 
Y.; Thiery, J. P. Functional relevance of a six mesenchymal gene signature in epithelial-
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mesenchymal transition (EMT) reversal by the triple angiokinase inhibitor, nintedanib 
(BIBF1120). Oncotarget 2015, 6, 22098-22113. (b) Zhang, Z.; Xie, Z.; Sun, G.; Yang, P.; Li, J.; 
Yang, H.; Xiao, S.; Liu, Y.; Qiu, H.; Qin, L.; Zhang, C.; Zhang, F.; Shan, B. Reversing drug 
resistance of cisplatin by HSP90 inhibitors in human ovarian cancer cells. Int. J. Clin. Exp. Med. 
2015, 8, 6687-6701. (c) Wu, W.; Yu, L-H; Ma, B.; Xu, M-J. The inhibitory effect of doxycycline 
on cisplatin-sensitive and -resistant epithelial ovarian cancer. PLoS One 2014, 9, e89841. (d) 
Fekete, M.; Santiskulvong, C.; Eng, C.; Dorigo, O. Effect of PI3K/AKT pathway inhibition-
mediated G1 arrest on chemosensitization in ovarian cancer cells. Anticancer Res. 2012, 32, 445-
452. (e) Tan, L.; Wang, J.; Tanizaki, J.; Huang, Z. F.; Aref, A. R.; Rusan, M.; Zhu, S. J.; Zhang, 
Y. Y.; Ercan, D.; Liao, R. G.; Capelletti, M.; Zhou, W. J.; Hur, W.; Kim, N.; Sim, T.; Gaudet, S.; 
Barbie, D. A.; Yeh, J. R. J.; Yun, C. H.; Hammerman, P. S.; Mohammadi, M.; Janne, P. A.; 
Gray, N. S. Development of covalent inhibitors that can overcome resistance to first-generation 
FGFR kinase inhibitors. Proc. Natl. Acad. Sci. U.S.A. 2014, 111, E4869-E4877. 
(36) For examples of SK-OV-3 murine xenograft studies see: (a) Shaw, T. J.; Senterman, M. 
K.; Dawson, K.; Crane, C. A.; Vanderhyden, B. C. Characterization of intraperitoneal, 
orthotopic, and metastatic xenograft models of human ovarian cancer. Mol. Ther. 2004, 10, 
1032-1042. (b) Faratian, D.; Zweemer, A. J. M.; Nagumo, Y.; Sims, A. H.; Muir, M.; Dodds, M.; 
Mullen, P.; Um, I.; Kay, C.; Hasmann, M.; Harrison, D. J.; Langdon, S. P. Trastuzumab and 
pertuzumab produce changes in morphology and estrogen receptor signaling in ovarian cancer 
xenografts revealing new treatment strategies. Clin. Cancer Res. 2011, 17, 4451-4461. (c) 
Zhang, A. L.; Shen, G. D.; Zhao, T.; Zhang, G. H.; Liu, J.; Song, L. H.; Wei, W.; Bing, L.; Wu, 
Z. S.; Wu, Q. Augmented inhibition of angiogenesis by combination of HER2 antibody ChA21 
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and trastuzumab in human ovarian carcinoma xenograft. J. Ovarian Res. 2010, 3, 20. (d) Li, W.; 
Ji, Z-L; Zhuo, G-C; Xu, R-J; Wang, J.; Hong, R-U. Effects of a selective cyclooxygenase-1 
inhibitor in SKOV-3 ovarian carcinoma xenograft-bearing mice. Med. Oncol. 2010, 27, 98-104. 
(e) Bauerschlag, D. O.; Schem, C.; Tiwari, S.; Egberts, J. H.; Weigel, M. T.; Kalthoff, H.; Jonat, 
W.; Maass, N.; Meinhold-Heerlein, I. Sunitinib (SU11248) inhibits growth of human ovarian 
cancer in xenografted mice. Anticancer Res. 2010, 30, 3355-3360. 
(37) Obach, R. S. Prediction of human clearance of twenty-nine drugs from hepatic 
microsomal intrinsic clearance data: an examination of in vitro half-life approach and 
nonspecific binding to microsomes. Drug Metab. Dispos. 1999, 27, 1350-1359. 
(38) The in-house HPLC method to measure LogD7.4 is based on: Kerns, E. H.; Li Di, L.; 
Petuskya, S.; Kleintop, T.; Huryn, D.; McConnell, O.; Carter, G. Pharmaceutical profiling 
method for lipophilicity and integrity using liquid chromatography-mass spectrometry. J. 
Chromatogr. B: Anal. Technol. Biomed. Life Sci. 2003, 791, 371-388. 
(39) The free-fraction in the cell assay was measured by dialysis using standard techniques, 
fua=0.47 (90%CI=0.54-0.42). Free GI50=GI50*fua 
(40) Hepatic blood flow (HBF) in mouse was assumed to be 90 ml/min/Kg. Sanoh, S.; 
Horiguchi, A.; Sugihara, K.; Kotake, Y.; Tayama, Y.; Ohshita, H.; Tateno, C.; Horie, T.; 
Kitamura, S.; Ohta, S. Prediction of in vivo hepatic clearance and half-life of drug candidates in 
human using chimeric mice with humanized liver. Drug Metab. Dispos. 2012, 40, 322-328. 
(41) Smith, D. A.; Kerns, E. H. The effect of plasma protein binding on in vivo efficacy: 
misconceptions in drug discovery. Nat. Rev. Drug Discovery 2010, 9, 929-939. 
Page 77 of 98
ACS Paragon Plus Environment
Journal of Medicinal Chemistry
1
2
3
4
5
6
7
8
9
10
11
12
13
14
15
16
17
18
19
20
21
22
23
24
25
26
27
28
29
30
31
32
33
34
35
36
37
38
39
40
41
42
43
44
45
46
47
48
49
50
51
52
53
54
55
56
57
58
59
60
  
77
                                                                                                                                                             
(42) Cav
0-24hrs=AUC0-24hrs/24 
(43) Smith, D. A.; Beaumont, K.; Maurer, T. S.; Di, Li. Volume of distribution in drug design. 
J. Med. Chem. 2015, 58, 5691-5698. 
(44) Assumes linear scaling of free exposure (AUCu) between different doses. 
(45) 2 mice were dosed at 30 mg/Kg po qd for 4 days and were then monitored for the 
following 3 days. Both mice retained good condition over that period as assessed by %body 
weight. See supporting information for details. 
(46) Smith, M. A.; Houghton, P. A proposal regarding reporting of in vitro testing results. Clin. 
Cancer Res. 2013, 19, 2828-2833. 
(47) The Tumor Growth Inhibition is defined as %TGI=(((Ct-C0)-(Tt-T0))/(Ct-C0))*100; 
Tt=arithmetic mean volume of treated tumors at time=t; T0=arithmetic mean volume of treated 
tumors at time=0; Ct= arithmetic mean volume of control tumors at time=t; C0=arithmetic mean 
volume control tumors at time=0. 
(48) The p-value refers to the comparison of untransformed arithmetic means of the treated and 
control arms using an unpaired Student’s t-test with Welch’s correction. The value is reported to 
2 significant figures.  
(49) de Billy, E. Powers, M. V.; Smith, J. R.; Workman, P. Drugging the heat shock factor 1 
pathway: exploitation of the critical cancer cell dependence on the guardian of the proteome. 
Cell Cycle 2009, 8, 3806-3808. 
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(50) http://www.cerep.fr/cerep/users/pages/catalog/profiles/DetailProfile.asp?profile=2121 
(August 31, 2016). 
(51) (a) https://www.evotec.com/uploads/media_library/36/2015-09_DDUp-
Services_Target__identification.pdf (August 31, 2016). (b) Sharma, K.; Weber, C.; Bairlein, M.; 
Greff, Z.; Kéri, G.; Cox, J.; Olsen, J. V.; Daub, H. Proteomics strategy for quantitative protein 
interaction profiling in cell extracts. Nat. Methods 2009, 6, 741-744. 
(52) Cheng, Y.; Prusoff, W. H. Relationship between the inhibition constant (K1) and the 
concentration of inhibitor which causes 50 per cent inhibition (I50) of an enzymatic reaction. 
Biochem. Pharmacol. 1973, 22, 3099-3108. 
(53) Trinkle-Mulcahy, L.; Boulon, S.; Lam, Y. W.; Urcia, R.; Boisvert, F-M; Vandermoere, F.; 
Morrice, N. A.; Swift, S.; Rothbauer, U.; Leonhardt, H.; Lamond, A. Identifying specific protein 
interaction partners using quantitative mass spectrometry and bead proteomes. J. Cell Biol. 2008, 
183, 223-239. 
(54) In-house data using a biotinylated bisamide derivative in a protein pull-down experiment 
also identified Pirin as a molecular target of the cellularly active bisamide series (data not 
shown). 
(55) Wendler, W. M. F.; Kremmer, E.; Forster; R.; Winnacker, E. L. Identification of pirin, a 
novel highly conserved nuclear protein. J. Biol. Chem. 1997, 272, 8482-8489. 
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(56) Dechend, R.; Hirano, F.; Lehmann, K.; Heissmeyer, V.; Ansieau, S.; Wulczyn, F. G.; 
Scheidereit, C.; Leutz, A. The BCL-3 oncoprotein acts as a bridging factor between NF-κB/REL 
and nuclear co-regulators. Oncogene 1999, 18, 3316-3323. 
(57) Liu, F.; Rehmania, I.; Esakia, S.; Fua, R.; Chena, L.; Serranoa, V.; Liu, A. Pirin is an iron-
dependent redox regulator of NF-κB. Proc. Nat. Acad. Sci. U.S.A. 2013, 110, 9722-9727. 
(58) (a) Brzoska, K.; Stepkowski, T. M.; Kruszewski, M. Basal PIR expression in HeLa Cells 
is driven by NRF2 via evolutionary conserved antioxidant response element. Mol. Cell. Biochem. 
2014, 389, 99-111. (b) Gelbman, B. D.; Heguy, A.; O'Connor, T. P.; Zabner, J.; Crystal, R. G. 
Upregulation of pirin expression by chronic cigarette smoking is associated with bronchial 
epithelial cell apoptosis. Respir. Res. 2007, 8, 10. 
(59) Qiao, Z.; Wang, D.; Hahn, J.; Ai, J.; Wang, Z. Pirin down-regulates the EAF2/U19 protein 
and alleviates its growth inhibition in prostate cancer cells. Prostate 2014, 74, 113-120. 
(60) Licciulli, S.; Luise, C.; Scafetta, G.; Capra, M.; Giardina, G.; Nuciforo, P.; Bosari, S.; 
Viale, G.; Mazzarol, G.; Tonelli, C.; Lanfrancone, L.; Alcalay, M. Pirin inhibits cellular 
senescence in melanocytic cells. Am. J. Pathol. 2011, 178, 2397-2406. 
(61) Miyazaki, I.; Simizu, S.; Okumura, H.; Takagi, S.; Osada, H. A small-molecule inhibitor 
shows that pirin regulates migration of melanoma cells. Nat. Chem. Biol. 2010, 6, 667-673. 
(62) Yamaoka, H.; Sumiyoshi, H.; Higashi, K.; Nakao, S.; Minakawa, K.; Sumida, K.; Saito, 
K.; Ikoma, N.; Mabuchi, T.; Ozawa, A.; Inagaki; Y. A novel small compound accelerates dermal 
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wound healing by modifying infiltration, proliferation and migration of distinct cellular 
components in mice. J. Dermatol. Sci. 2014, 74, 204-213. 
(63) (a) Komai, K.; Niwa, Y.; Sasazawa, Y.; Simizu, S. Pirin regulates epithelial to 
mesenchymal transition independently of BCL3-SLUG signaling. FEBS Lett. 2015, 589, 738-
743. (b) Marcucci, F.; Stassi, G.; De Maria, R. Epithelial–mesenchymal transition: a new target 
in anticancer drug discovery. Nat. Rev. Drug Discovery 2016, 15, 311-325. 
(64) In-house studies using siRNA to inhibit pirin synthesis in SK-OV-3 cells demonstrated 
only limited effects on proliferation. Further studies are ongoing. 
(65) TPh A was purchased from Sigma-Aldrich: 
http://www.sigmaaldrich.com/catalog/product/sigma/t6205?lang=en&region=GB (August 31, 
2016). 
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Figure 1. Inhibitors of HSF1-mediated transcriptional activity  
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Figure 2. HSF1 pathway inhibitor, bisamide 1 (CCT245232)  
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Figure 3. Efficacy of bisamide 26 against SK-OV-3 human ovarian carcinoma xenograft model. Blue: vehicle 
control n=8, Red: 26 at 20 mg/Kg po qd n=8, (Vehicle=10% DMSO, 90% of a 25% (2-hydroxypropyl)-β-
cyclodextrin in 50 mM citrate buffer pH 5). Error bars: arithmetic mean±SEM. Dosing breaks were carried 
out on days 5-12, 14, 16, 18, 20, 22, 24, 26, 29, 31.  
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Figure 4. Tool compounds for target identification. All quoted cellular activities are in the SK- OV-3 cell line, 
the numbers of repeats are in parentheses  
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Figure 5. Representative SPR sensorgram and binding isotherm of bisamide 26 bound to recombinant pirin. 
The dotted-line represents the time-point the equilibrium response was measured. The binding isotherm was 
fitted to a one-site specific binding model using Graphpad Prism 6.  
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Figure 6. X-ray crystal structure of bisamide 26. PDB 5JCT, Pymol image of pirin (light blue cartoon 
representation) in complex with bisamide 26 (cyan stick representation), 2 Fo-Fc map contoured at 1.0 σ 
(blue mesh) and Pymol image of pirin (magenta, blue stick representation) in complex with bisamide 26 
(cyan stick representation), distances shown are in Ångstroms, 2 Fo-Fc map contoured at 1.0 σ (blue mesh). 
Crystals belonged to the space group P212121 and diffracted to resolution of 1.73 Å.  
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Figure 7. The anti-migratory activity of chemical probe bisamide 26. A: wound healing images of WM266.4 
cells, after 30 h the wound has almost completely healed in the control in contrast to 100 nM 26. B: 
quantification of the relative wound density reveals the maximum anti- migratory activity is achieved at 100 
nM 26.  
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Scheme 1. Synthesis of the benzodioxane bisamide replacements.  
Reagents and conditions: (i) O  
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Scheme 2. Synthesis of solubilizing group analogues  
Reagents and conditions: (i) O  
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Table 4. Molecular targets from the pull-down assay using the bisamide probes in SK-OV-3 cell lysate  
A: SK-OV-3 cell lysate protein  
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